Antisense oligonucleotides targeting UNC13A

By using antisense oligonucleotide splicing regulators to complement UNC13A precursor-mRNA, the problem of changes in splicing patterns caused by TDP-43 depletion was solved, the expression of UNC13A protein was improved, and neuronal cell function was improved, and the potential The effect of treating neurological diseases.

CN118974254APending Publication Date: 2024-11-15F HOFFMANN LA ROCHE & CO AG
View PDF 18 Cites 0 Cited by

Patent Information

Application Number
CN202280083648.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2021-12-21
Filing Date
2022-12-20
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

TDP-43 depletion leads to changes in UNC13A mRNA splicing pattern, affecting neuronal cell function, and the existing technology is difficult to effectively solve this problem.

Method used

The use of antisense oligonucleotide splicing regulators complements UNC13A precursor-mRNA to increase or restore UNC13A expression to improve the harmful effects of TDP-43 depletion on neuronal cells.

Benefits of technology

By increasing the expression of wild-type UNC13A protein, reducing poorly functional UNC13A mutant polypeptides can potentially improve the therapeutic effect of related neurological diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004896187020000371
    Figure BDA0004896187020000371
  • Figure BDA0004896187020000381
    Figure BDA0004896187020000381
  • Figure BDA0004896187020000391
    Figure BDA0004896187020000391
Patent Text Reader

Abstract

The present invention relates to an antisense oligonucleotide splicing modulator Unc-13 homolog A (UNC13A). These antisense oligonucleotide splice modulators are complementary, such as fully complementary, to UNC13A precursor-mRNA, and are capable of increasing or restoring expression of UNC13A in TDP-43 depleted cells, such as for use in conditions and medical indications in which TDP-43 has been functionally depleted.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention relates to antisense oligonucleotide splicing regulators of Unc-13 homolog A (UNC13A). These antisense oligonucleotide splicing regulators are complementary to UNC13A pre-mRNA, such as fully complementary, and are capable of increasing or restoring the expression of UNC13A in TDP-43-depleted cells, such as for use in conditions and medical indications in which TDP-43 is functionally depleted. Background Art

[0002] TAR DNA-binding protein 43 (TDP-43) is a multifunctional RNA / DNA binding protein involved in RNA-related metabolism. Dysregulation of TDP-43 deposits functions as inclusions in the brain and spinal cord of patients with motor neuron diseases: amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) (Prasad et al., Front. Mol. Neurosci., 2019).

[0003] TDP-43 depletion is manifested in a range of diseases, referred to as TDP-43 pathology, and includes diseases such as amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration (FTLD), progressive supranuclear palsy (PSP), primary lateral sclerosis, progressive muscular dystrophy, Alzheimer's disease, Parkinson's disease, autism, hippocampal sclerosis dementia, Down syndrome, Huntington's disease, polyglutamine diseases such as spinocerebellar ataxia 3, myopathies, and chronic traumatic encephalopathy.

[0004] UNC13A protein binds to phorbol esters and diacylglycerol and is involved in the release of transmitters at synapses.

[0005] We show that splicing of UNC13A is at least partially controlled by TDP-43 due to the presence of TDP-43 binding sites within the UNC13A pre-mRNA sequence. Summary of the invention

[0006] The inventors surprisingly determined that if TDP-43 is depleted in cells, UNC13A mRNA splicing is altered.

[0007] Therefore, the inventors hypothesized that modifying the UNC13A splicing pattern might be able to ameliorate the deleterious effects of TDP-43 depletion on neuronal cells.

[0008] Here, the inventors used antisense oligonucleotides, UNC13A splicing regulators, to increase the expression of UNC13A.

[0009] In one aspect, the present invention provides an antisense oligonucleotide Unc-13 homolog A (UNC13A) splicing regulator, wherein the antisense oligonucleotide splicing regulator is 8 to 40 nucleotides in length and comprises a contiguous nucleotide sequence of at least 8 nucleotides in length that is complementary to UNC13A pre-mRNA.

[0010] In some embodiments, antisense oligonucleotide splicing regulators may be able to increase the expression of Unc-13 homolog A () in TDP-43-depleted cells.

[0011] In some embodiments, antisense oligonucleotide splicing modulators may be able to reduce expression of a UNC13A mutant polypeptide, such as a splice variant of UNC13A, in TDP-43-depleted cells.

[0012] The inventors surprisingly determined that in TDP-43 depleted cells, increased expression of UNC13A splice variants including additional exons was observed. This resulted in reduced production of functionally active wild-type (WT) UNC13A polypeptides. Thus, in some embodiments, a splice variant may comprise a polypeptide sequence encoded by an additional exon when compared to a wild-type UNC13A polypeptide sequence.

[0013] In some embodiments, a mutant UNC13A splice variant may comprise an insertion, such as an insertion of about 128 or / and 178 nucleotides, when compared to conventionally spliced ​​UNC13A mature mRNA.

[0014] In some embodiments, the insertion may result in a frameshift.

[0015] In some embodiments, the insertion may result in a premature stop codon, which can target the transcript for nonsense-mediated decay (NMD).

[0016] In some embodiments, the contiguous nucleotide sequence of the antisense oligonucleotide splicing regulator can be complementary to a splicing enhancer site in the UNC13A pre-mRNA.

[0017] In some embodiments, the contiguous nucleotide sequence of the antisense oligonucleotide splicing regulator may be complementary to a sequence selected from SEQ ID NOs: 554-558.

[0018] In some embodiments, the contiguous nucleotide sequence of the antisense oligonucleotide splicing regulator may be complementary to a sequence selected from SEQ ID NOs: 8-279.

[0019] In some embodiments, the contiguous nucleotide sequence of the antisense oligonucleotide splicing regulator can be complementary to a sequence selected from the group consisting of: SEQ ID NO: 62; SEQ ID NO: 66, SEQ ID NO: 68, SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 76, SEQ ID NO: 112, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 117, SEQ ID NO: 122, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142 NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 146, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 178, SEQ ID NO: 179, SEQ ID NO: 183, SEQ ID NO: 187, SEQ ID NO: 189, SEQ ID NO: 192, SEQ ID NO: 193, SEQ ID NO: 214, SEQ ID NO: 247, SEQ ID NO: 252, SEQ ID NO: 254, SEQ ID NO: 258, SEQ ID NO: 273, SEQ ID NO: 276, SEQ ID NO:277, SEQ ID NO:278 and SEQ ID NO:279.

[0020] In some embodiments, the contiguous nucleotide sequence of the antisense oligonucleotide splicing regulator can be complementary to a sequence selected from the group consisting of SEQ ID NO: 66, SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 76, SEQ ID NO: 122, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 146, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 273, SEQ ID NO: 276, SEQ ID NO: 277 and SEQ ID NO: 279.

[0021] In some embodiments, the contiguous nucleotide sequence of the antisense oligonucleotide splicing regulator may be a sequence selected from SEQ ID NOs 280 to 551, or at least 10 contiguous nucleotides thereof.

[0022] In some embodiments, the contiguous nucleotide sequence of the antisense oligonucleotide splicing regulator can be a sequence selected from the group consisting of: SEQ ID NO: 334; SEQ ID NO: 338; SEQ ID NO: 340; SEQ ID NO: 342; SEQ ID NO: 344; SEQ ID NO: 345; SEQ ID NO: 346; SEQ ID NO: 348; SEQ ID NO: 384; SEQ ID NO: 386; SEQ ID NO: 387; SEQ ID NO: 389; SEQ ID NO: 394; SEQ ID NO: 397; SEQ ID NO: 398; SEQ ID NO: 399; SEQ ID NO: 400; SEQ ID NO: 401; SEQ ID NO: 402; SEQ ID NO: 403; SEQ ID NO: 405; SEQ ID NO: 406; SEQ ID NO: 407; SEQ ID NO: 408; SEQ ID NO: 409; SEQ ID NO: 410; SEQ ID NO: 411; SEQ ID NO: 412; SEQ ID NO: 413; SEQ ID NO: 414; SEQ ID NO: 415 SEQ ID NO: 413; SEQ ID NO: 414; SEQ ID NO: 415; SEQ ID NO: 418; SEQ ID NO: 423; SEQ ID NO: 424; SEQ ID NO: 425; SEQ ID NO: 426, SEQ ID NO: 427, SEQ ID NO: 428, SEQ ID NO: 434, SEQ ID NO: 435, SEQ ID NO: 450, SEQ ID NO: 451, SEQ ID NO: 455, SEQ ID NO: 459, SEQ ID NO: 461, SEQ ID NO: 464, SEQ ID NO: 465, SEQ ID NO: 486, SEQ ID NO: 519, SEQ ID NO: 524, SEQ ID NO: 526, SEQ ID NO: 530, SEQ ID NO: 545, SEQ ID NO: 548, SEQ ID NO: 549, SEQ ID NO: 550 and SEQ ID NO: 551, or at least 10 consecutive nucleotides thereof.

[0023] In some embodiments, the contiguous nucleotide sequence of the antisense oligonucleotide splicing regulator can be a sequence selected from the group consisting of SEQ ID NO: 338, SEQ ID NO: 342, SEQ ID NO: 344, SEQ ID NO: 345, SEQ ID NO: 346, SEQ ID NO: 348, SEQ ID NO: 394, SEQ ID NO: 397, SEQ ID NO: 398, SEQ ID NO: 399, SEQ ID NO: 400, SEQ ID NO: 401, SEQ ID NO: 402, SEQ ID NO: 403, SEQ ID NO: 405, SEQ ID NO: 406, SEQ ID NO: 407, SEQ ID NO: 408, SEQ ID NO: 409, SEQ ID NO: 410, SEQ ID NO: 411, SEQ ID NO: 412, SEQ ID NO: 413, SEQ ID NO: 414, SEQ ID NO: 415, SEQ ID NO: 418, SEQ ID NO: 423, SEQ ID NO: 424, SEQ ID NO: 425 NO:424, SEQ ID NO:426, SEQ ID NO:427, SEQ ID NO:428, SEQ ID NO:434, SEQ ID NO:435, SEQ ID NO:545, SEQ ID NO:548, SEQ ID NO:549 and SEQ ID NO:551, or at least 10 consecutive nucleotides thereof.

[0024] In some embodiments, the antisense oligonucleotide splicing modulator may be at least 12 nucleotides in length, such as at least 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, or 32 nucleotides in length.

[0025] In some embodiments, the contiguous nucleotide sequence of the antisense oligonucleotide splicing regulator can have the same length as the antisense oligonucleotide splicing regulator.

[0026] In some embodiments, the antisense oligonucleotide splicing regulator may comprise one or more modified nucleosides, such as 2′ sugar modified nucleosides, which may be independently selected from the group consisting of: 2′-O-alkyl-RNA; 2′-O-methyl RNA (2′-OMe); 2′-alkoxy-RNA; 2′-O-methoxyethyl-RNA (2′-MOE); 2′-amino-DNA; 2′-fluoro-RNA; 2′-fluoro-DNA; arabino nucleic acid (ANA); 2′-fluoro-ANA; locked nucleic acid (LNA); or any combination thereof.

[0027] In some embodiments, the contiguous nucleotide sequence of the antisense oligonucleotide splicing modulator may comprise 2'-O-methoxyethyl-RNA (2'-MOE) nucleosides, optionally linked by phosphorothioate internucleoside linkages.

[0028] In some embodiments, one or more of the modified nucleosides is a locked nucleic acid nucleoside (LNA), such as an LNA nucleoside selected from the group consisting of constrained ethyl nucleoside (cEt) and β-D-oxy-LNA.

[0029] In some embodiments, the contiguous nucleotide sequence of the antisense oligonucleotide splicing regulator may be at least 75%, such as at least 80%, at least 85%, at least 90%, or at least 95% complementary to the UNC13A pre-mRNA sequence.

[0030] In other embodiments, the contiguous nucleotide sequence of the contiguous nucleotide sequence may be completely complementary to the UNC13A pre-mRNA.

[0031] In some embodiments, the antisense oligonucleotide splicing modulator may not comprise a region of more than 3 or more than 4 consecutive DNA nucleosides, and may not be capable of mediating RNase H cleavage.

[0032] In some embodiments, one or more or all of the internucleoside bonds within the antisense oligonucleotide splicing regulator may be modified. For example, the modified internucleoside bonds may comprise phosphorothioate bonds.

[0033] In some embodiments, the antisense oligonucleotide splicing modulator may be covalently linked to at least one conjugate moiety.

[0034] In some embodiments, the antisense oligonucleotide splicing modulators may be in the form of a pharmaceutically acceptable salt, such as a sodium salt or a potassium salt.

[0035] In another aspect, a pharmaceutical composition is provided, comprising the antisense oligonucleotide splicing regulator of the present invention and a pharmaceutically acceptable diluent, solvent, carrier, salt and / or adjuvant.

[0036] In another aspect, a method for increasing UNC13A expression in a cell, such as an in vivo or in vitro method, is provided, the method comprising administering to the cell an effective amount of an antisense oligonucleotide splicing regulator or pharmaceutical composition of the invention, the cell possibly expressing abnormal levels of or exhibiting depleted levels of TDP-43.

[0037] In another aspect, the present invention provides a method for treating or preventing a disease in a subject, the method comprising administering a therapeutically or prophylactically effective amount of the antisense oligonucleotide splicing regulator or pharmaceutical composition of the present invention to a subject suffering from or susceptible to the disease.

[0038] In another aspect, there is provided an antisense oligonucleotide splicing regulator or pharmaceutical composition of the invention for use as a medicament.

[0039] In another aspect, provided is an antisense oligonucleotide splicing regulator or pharmaceutical composition of the invention for use in the treatment or prevention of a disease in a subject.

[0040] In another aspect, provided is an antisense oligonucleotide splicing regulator or a pharmaceutical composition of the present invention for use in preparing a medicament for treating or preventing a disease in a subject.

[0041] In all aspects of the invention, the disease may be a neurological disorder selected from the group consisting of amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration (FTLD), progressive supranuclear palsy (PSP), primary lateral sclerosis, progressive muscular atrophy, Alzheimer's disease, Parkinson's disease, autism, hippocampal sclerosis dementia, Down syndrome, Huntington's disease, polyglutamine diseases such as spinocerebellar ataxia 3, myopathy and chronic traumatic encephalopathy.

[0042] In certain embodiments, the disease may be a neurological disorder selected from the group consisting of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). BRIEF DESCRIPTION OF THE DRAWINGS

[0043] Figure 1 A screenshot of the CLC Genomics Workbench software is shown, where the NGS read mapping of the UNC13A gene can be seen. The inclusion of a new exon in a sample treated with Compound A (SEQ ID 553) is shown. The arrows show two possible uses of the splice acceptor site, namely the inclusion of a 128 or 178 bp exon, both of which would result in a frameshift and transcript for nonsense-mediated decay.

[0044] Figure 2 A graphic representation showing the locations of screening ASO binding sites on UNC13A pre-mRNA and the ability of ASOs to restore UNC13A expression by inhibiting the inclusion of two new exons. The locations of the two new exons included in the UNC13A transcript are shown at the bottom with black bars. The locations of the exons are shown according to the hg38 gene annotation, and the UNC13A gene is expressed from the minus strand. DETAILED DESCRIPTION

[0045] The inventors have identified that the splicing of UNC13A is affected by TDP-43. This is thought to result in the production of non-functional or poorly functional UNC13A in TDP-43 cells.

[0046] Without being bound by theory, it is believed that in TDP-43 depleted cells UNC13A can be spliced ​​so as to include one or more additional exons, such as one or two additional exons. This additional exon may be 128 or 178 nucleotides in length. The inclusion of one or more additional exons may result in a frameshift. This may result in premature stop codons that may target transcripts for nonsense-mediated decay. This will result in a reduction in wild-type UNC13A polypeptide. This alternatively spliced ​​mRNA transcript is referred to herein as a "mutant UNC13A mRNA," "mutant UNC13A transcript," "splice variant of UNC13A," or "UNC13A splice variant."

[0047] The inventors have also determined that antisense oligonucleotide splicing regulators can be used to reduce the production of UNC13A splicing variants. Herein, the antisense oligonucleotide splicing regulators of the invention may also be referred to as oligonucleotides of the invention or antisense oligonucleotides of the invention.

[0048] The oligonucleotide splicing regulators of the invention can target splicing enhancer sites in UNC13A pre-mRNA. This may reduce alternative splicing, thereby increasing conventional splicing and the production of wild-type UNC13A protein.

[0049] Enhanced wild-type UNC13A expression is ideal for treating a range of disorders characterized by or caused by reduced UNC13A expression. These include amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration (FTLD), progressive supranuclear palsy (PSP), primary lateral sclerosis, progressive muscular atrophy, Alzheimer's disease, Parkinson's disease, autism, hippocampal sclerosis dementia, Down syndrome, Huntington's disease, polyglutamine diseases such as spinocerebellar ataxia 3, myopathy, and chronic traumatic encephalopathy.

[0050] Splicing regulation

[0051] The antisense oligonucleotides of the invention are UNC13A splicing modulators, ie they affect the splicing of UNC13A pre-mRNA. Herein, the oligonucleotides of the invention may be referred to as "antisense oligonucleotide splicing modulators".

[0052] In some embodiments, the antisense oligonucleotide splicing regulators of the invention may be complementary to UNC13A pre-mRNA.

[0053] In some embodiments, the UNC13A pre-mRNA may have a sequence of SEQ ID NO 1. SEQ ID NO 1 provided herein is a reference sequence, and it is understood that the target pre-mRNA may be an allelic variant of SEQ ID NO 1, such as an allelic variant comprising one or more polymorphisms.

[0054] In some embodiments, antisense oligonucleotide splicing modulators may be able to increase expression of UNC13A in TDP-43 depleted cells.Herein, it is expected that expression of wild-type (ie, conventionally spliced) UNC13A will be increased by exposure to antisense oligonucleotide splicing modulators of the invention.

[0055] Without being bound by theory, it is believed that the antisense oligonucleotide splicing regulators of the present invention can increase the conventional splicing of UNC13A pre-mRNA. This is believed to result in an increase in the amount of conventionally spliced ​​mature UNC13A mRNA, which in turn is believed to result in an increase in the amount of wild-type UNC13A protein.

[0056] Herein, the terms "wild type" and "conventional splicing" will be used interchangeably.

[0057] In some embodiments, the wild-type (i.e., conventionally spliced) mature UNC13A mRNA sequence may have the sequence of SEQ ID NO: 2, or a fragment or variant thereof. SEQ ID NO 2 provided herein is a reference sequence, and it is understood that the conventionally spliced ​​UNC13A mRNA may be an allelic variant of SEQ ID NO 2, such as an allelic variant comprising one or more polymorphisms.

[0058] In some embodiments, the wild-type UNC13A protein may have the sequence of SEQ ID NO: 3, or a fragment or variant thereof. SEQ ID NO 3 provided herein is a reference sequence, and it is understood that the wild-type UNC13A protein may be an allelic variant of SEQ ID NO 3, such as an allelic variant comprising one or more polymorphisms.

[0059] Herein, the term "increasing the expression of wild-type UNC13A" is understood to mean increasing conventionally spliced ​​UNC13A mRNA levels, increasing wild-type UNC13A protein levels, or increasing conventionally spliced ​​UNC13A mRNA levels and wild-type UNC13A protein levels.

[0060] In certain embodiments, the antisense oligonucleotide splicing regulators of the invention can increase conventional splicing of UNC13A pre-mRNA by at least about 10% compared to a control. More preferably, the antisense oligonucleotide splicing regulators of the invention can increase conventional splicing of UNC13A pre-mRNA by at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 200%, at least about 300%, at least about 400%, at least about 500%, at least about 600% or more compared to a control.

[0061] In certain embodiments, the antisense oligonucleotide splicing regulators of the invention can increase the amount of wild-type UNC13A protein by at least about 10% compared to a control. More preferably, the antisense oligonucleotide splicing regulators of the invention can increase the amount of wild-type UNC13A protein by at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 200%, at least about 300%, at least about 400%, at least about 500%, at least about 600% or more compared to a control.

[0062] In certain embodiments, the antisense oligonucleotide splicing regulators of the invention can increase conventional splicing of UNC13A pre-mRNA and increase the amount of wild-type UNC13A protein by at least about 10% compared to a control. More preferably, the antisense oligonucleotide splicing regulators of the invention can increase conventional splicing of UNC13A pre-mRNA and increase the amount of wild-type UNC13A protein by at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 200%, at least about 300%, at least about 400%, at least about 500%, at least about 600% or more compared to a control.

[0063] Preferably, the antisense oligonucleotide splicing regulators of the present invention increase the amount of wild-type UNC13A by reducing the expression of UNC13A mutant mRNA in TDP-43-depleted cells.

[0064] The UNC13A mutant mRNA may be a splice variant of UNC13A. Herein, the term "splicing variant" or "splice variant" includes, but is not limited to, a variant mature mRNA comprising one or more additional exons relative to the wild-type UNC13A mature mRNA sequence. The wild-type UNC13A mature mRNA sequence may be SEQIS NO 2.

[0065] In some embodiments, the inclusion of additional exons within the UNC13A mature mRNA sequence may result in a frameshift. This may lead to premature stop codons and nonsense-mediated decay.

[0066] In some embodiments, inclusion of additional exons may result in translation of a UNC13A mutant polypeptide.

[0067] In some embodiments, the UNC13A mutant polypeptide may be encoded by the nucleotide sequence of SEQ ID NO: 4, or a fragment or variant thereof. SEQ ID NO 4 provided herein is a reference sequence, and it is understood that the nucleic acid sequence encoding the mutant UNC13A polypeptide may be an allelic variant of SEQ ID NO 4, such as an allelic variant comprising one or more polymorphisms.

[0068] In other embodiments, the UNC13A mutant polypeptide may have the sequence of SEQ ID NO: 5, or a fragment or variant thereof. SEQ ID NO 5 provided herein is a reference sequence, and it is understood that the mutant UNC13A may be an allelic variant of SEQ ID NO 5, such as an allelic variant comprising one or more polymorphisms.

[0069] In some embodiments, the UNC13A mutant polypeptide may be encoded by the nucleotide sequence of SEQ ID NO: 6, or a fragment or variant thereof. SEQ ID NO 6 provided herein is a reference sequence, and it is understood that the nucleic acid sequence encoding the mutant UNC13A polypeptide may be an allelic variant of SEQ ID NO 6, such as an allelic variant comprising one or more polymorphisms.

[0070] In other embodiments, the UNC13A mutant polypeptide may have the sequence of SEQ ID NO: 7, or a fragment or variant thereof. SEQ ID NO 7 provided herein is a reference sequence, and it is understood that the mutant UNC13A may be an allelic variant of SEQ ID NO 7, such as an allelic variant comprising one or more polymorphisms.

[0071] Herein, the term "reducing the expression of UNC13A mutants" is understood to mean reducing the level of alternatively spliced ​​UNC13A mature mRNA, reducing the level of mutant UNC13A polypeptides, or reducing the level of alternatively spliced ​​UNC13A mature mRNA and reducing the level of mutant UNC13A polypeptides. This term also encompasses reducing the production of alternatively spliced ​​UNC13A mRNA, even if the alternatively spliced ​​mature mRNA is ultimately degraded by nonsense-mediated degradation.

[0072] In some embodiments, the antisense oligonucleotide splicing regulator of the invention is capable of reducing the level of alternatively spliced ​​UNC13A mature mRNA by at least 10% compared to a control. More preferably, the antisense oligonucleotide splicing regulator of the invention is capable of reducing the level of alternatively spliced ​​UNC13A mature mRNA by at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 200%, at least about 300%, at least about 400%, at least about 500%, at least about 600% or more compared to a control.

[0073] In some embodiments, the antisense oligonucleotide splicing regulators of the invention are capable of reducing the level of a mutant UNC13A polypeptide by at least 10% compared to a control. More preferably, the antisense oligonucleotide splicing regulators of the invention are capable of reducing the level of a mutant UNC13A polypeptide by at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 200%, at least about 300%, at least about 400%, at least about 500%, at least about 600% or more compared to a control.

[0074] In some embodiments, the antisense oligonucleotide splicing regulators of the invention are capable of reducing the level of alternatively spliced ​​UNC13A mature mRNA and reducing the level of mutant UNC13A polypeptide by at least 10% compared to a control. More preferably, the antisense oligonucleotide splicing regulators of the invention are capable of reducing the level of alternatively spliced ​​mature UNC13A mRNA and reducing the level of mutant UNC13A polypeptide by at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 200%, at least about 300%, at least about 400%, at least about 500%, at least about 600% or more compared to a control.

[0075] Comparison

[0076] When the term "control" is used in connection with measuring the effect of an antisense oligonucleotide splicing modulator, it is generally understood that the control is a cell that has not been exposed to an antisense oligonucleotide splicing modulator of the invention.

[0077] Alternatively, an increase in wild-type UNC13A expression or a decrease in UNC13A mutant expression can be determined by reference to the amount of wild-type and / or mutant UNC13A mRNA and / or polypeptide expressed prior to exposure to the antisense oligonucleotide splicing modulators of the invention.

[0078] In other embodiments, the control can be cells treated with a non-targeting oligonucleotide.

[0079] In some embodiments, the control can be a mock transfection, for example, where the cells are treated with PBS.

[0080] Oligonucleotides

[0081] As used herein, the term "oligonucleotide" is defined as a molecule comprising two or more covalently linked nucleosides as generally understood by those skilled in the art. Such covalently linked nucleosides may also be referred to as nucleic acid molecules or oligomers.

[0082] Oligonucleotides are typically prepared in the laboratory by solid phase chemical synthesis followed by purification and isolation. When referring to the sequence of an oligonucleotide, reference is made to the sequence or order of the covalently linked nucleotides or nucleobase portions of a nucleoside or modifications thereof. The antisense oligonucleotide splicing regulators of the present invention are artificial and chemically synthesized and are typically purified or isolated. The antisense oligonucleotide splicing regulators of the present invention may comprise one or more modified nucleosides, such as 2' sugar modified nucleosides. The antisense oligonucleotide splicing regulators of the present invention may comprise one or more modified internucleoside bonds, such as one or more phosphorothioate internucleoside bonds.

[0083] In some embodiments, the antisense oligonucleotide splicing modulators of the invention are single-stranded oligonucleotides.

[0084] In some embodiments, the antisense oligonucleotide splicing modulators of the invention are 8 to 40 nucleotides in length.

[0085] In some embodiments, the antisense oligonucleotide splicing regulators of the invention are 8 to 40 nucleotides in length and comprise a contiguous nucleotide sequence of 8 to 40 nucleotides.

[0086] In some embodiments, the antisense oligonucleotide splicing regulators of the invention are 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides in length.

[0087] In some embodiments, the antisense oligonucleotide splicing modulators of the invention are at least 12 nucleotides in length.

[0088] In some embodiments, the antisense oligonucleotide splicing modulators of the invention are at least 14 nucleotides in length.

[0089] In some embodiments, the antisense oligonucleotide splicing modulators of the invention are at least 16 nucleotides in length.

[0090] In some embodiments, the antisense oligonucleotide splicing modulators of the invention are at least 18 nucleotides in length.

[0091] Preferably, the antisense oligonucleotide splicing regulators of the present invention are 16 to 20 nucleotides in length.

[0092] More preferably, the antisense oligonucleotide splicing regulators of the present invention are 18 to 20 nucleotides in length.

[0093] Continuous nucleotide sequence

[0094] As used herein, the term "contiguous nucleotide sequence" refers to the region of the antisense oligonucleotide splicing regulator of the present invention that is complementary to the target nucleic acid, which may be or may include an oligonucleotide motif sequence. In this article, the term is used interchangeably with "contiguous nucleobase sequence".

[0095] The antisense oligonucleotide splicing regulator comprises a contiguous nucleotide sequence and may optionally comprise one or more additional nucleotides, such as a nucleotide linker region that can be used to connect a functional group (e.g., a conjugate group) to the contiguous nucleotide sequence. The nucleotide linker region may be complementary or non-complementary to the target nucleic acid.

[0096] It is to be understood that the contiguous nucleotide sequence of the antisense oligonucleotide splicing modulator cannot be longer than the antisense oligonucleotide splicing modulator itself, and the antisense oligonucleotide splicing modulator cannot be shorter than the contiguous nucleotide sequence.

[0097] In some embodiments, the entire nucleotide sequence of the antisense oligonucleotide splicing regulator of the present invention is a contiguous nucleotide sequence.

[0098] A contiguous nucleotide sequence is a sequence of nucleotides in the antisense oligonucleotide splicing regulators of the invention that is complementary, and in some cases completely complementary, to a target nucleic acid, target sequence, or target site sequence.

[0099] In some embodiments, the contiguous nucleotide sequence is 8 to 40 nucleotides in length.

[0100] In some embodiments, the contiguous nucleotide sequence is 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides in length.

[0101] In some embodiments, the contiguous nucleotide sequence is at least 12 nucleotides in length.

[0102] In some embodiments, the contiguous nucleotide sequence is at least 14 nucleotides in length.

[0103] In some embodiments, the contiguous nucleotide sequence is at least 16 nucleotides in length.

[0104] In some embodiments, the contiguous nucleotide sequence is at least 18 nucleotides in length.

[0105] In a preferred embodiment, the contiguous nucleotide sequence is 16 to 20 nucleotides in length.

[0106] More preferably, the length of the contiguous nucleotide sequence is 18 to 20 nucleotides.

[0107] In some embodiments, the antisense oligonucleotide splicing modulators of the invention consist of a contiguous nucleotide sequence.

[0108] In some embodiments, the antisense oligonucleotide splicing modulators of the invention are contiguous nucleotide sequences.

[0109] Antisense oligonucleotide splicing regulators targeting UNC13A pre-mRNA

[0110] The antisense oligonucleotide splicing regulators of the present invention comprise a continuous nucleotide sequence complementary to UNC13A pre-mRNA.

[0111] The UNC13A pre-mRNA can be described as a continuous nucleotide sequence or a target of an antisense oligonucleotide splicing modulator. In other words, the antisense oligonucleotide splicing modulator targets the UNC13A pre-mRNA.

[0112] In some embodiments, the target sequence may have a sequence of SEQ ID NO 1 or a fragment thereof. SEQ ID NO 1 provided herein is a reference sequence, and it is understood that the UNC13A pre-mRNA sequence may be an allelic variant of SEQ ID NO 1, such as an allelic variant comprising one or more polymorphisms. The same applies to all sequences identified as target sequences herein.

[0113] In one aspect, the present invention relates to an antisense oligonucleotide splicing regulator, wherein the antisense oligonucleotide splicing regulator is 8 to 40 nucleotides in length and comprises a continuous nucleotide sequence complementary to SEQ ID NO 1 with a length of at least 8 nucleotides.

[0114] In some embodiments, the antisense oligonucleotide splicing regulators of the invention comprise a contiguous sequence that is at least about 75% complementary, at least about 80% complementary, at least about 85% complementary, at least about 90% complementary, at least about 95% complementary, or fully complementary (i.e., 100% complementary) to SEQ ID NO 1. Here, complementarity is determined over the length of the contiguous nucleotide sequence.

[0115] In some embodiments, the antisense oligonucleotide splicing regulator of the present invention comprises a contiguous sequence that is at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% complementary or fully complementary (i.e., 100% complementary) to SEQ ID NO 1.

[0116] In some embodiments, the antisense oligonucleotide splicing regulators of the invention comprise a contiguous sequence that may comprise one, two, or three mismatches between the contiguous nucleotide sequence and the target nucleic acid.

[0117] In a preferred embodiment, the oligonucleotide of the present invention or its contiguous nucleotide sequence is completely complementary (100% complementary) to SEQ ID NO 1 over the length of the contiguous nucleotide sequence.

[0118] In one embodiment, the contiguous nucleotide sequence is complementary to a splicing enhancer site in the UNC13A pre-mRNA.

[0119] One aspect of the present invention relates to an antisense oligonucleotide splicing regulator comprising a contiguous nucleotide sequence complementary to SEQ ID NO 554 and having a length of 8 to 40 nucleotides.

[0120] In some embodiments, the antisense oligonucleotide splicing regulator of the present invention comprises a continuous sequence that is at least 90% complementary to SEQ ID NO554, such as at least 91%, such as at least 92%, such as at least 93%, such as at least 94%, such as at least 95%, such as at least 96%, such as at least 97%, such as at least 98% or 100% complementary.

[0121] In a preferred embodiment, the antisense oligonucleotide splicing regulator of the present invention comprises a contiguous sequence that is completely complementary to SEQ ID NO 554 (ie, 100% complementary).

[0122] One aspect of the present invention relates to an antisense oligonucleotide splicing regulator comprising a contiguous nucleotide sequence complementary to SEQ ID NO 555 and having a length of 8 to 40 nucleotides.

[0123] In some embodiments, the antisense oligonucleotide splicing regulator of the present invention comprises a continuous sequence that is at least 90% complementary to SEQ ID NO 555, such as at least 91%, such as at least 92%, such as at least 93%, such as at least 94%, such as at least 95%, such as at least 96%, such as at least 97%, such as at least 98% or 100% complementary.

[0124] In a preferred embodiment, the antisense oligonucleotide splicing regulator of the present invention comprises a contiguous sequence that is completely complementary to SEQ ID NO 555 (ie, 100% complementary).

[0125] One aspect of the present invention relates to an antisense oligonucleotide splicing regulator comprising a contiguous nucleotide sequence complementary to SEQ ID NO 556 and having a length of 8 to 40 nucleotides.

[0126] In some embodiments, the antisense oligonucleotide splicing regulator of the present invention comprises a continuous sequence that is at least 90% complementary to SEQ ID NO556, such as at least 91%, such as at least 92%, such as at least 93%, such as at least 94%, such as at least 95%, such as at least 96%, such as at least 97%, such as at least 98% or 100% complementary.

[0127] In a preferred embodiment, the antisense oligonucleotide splicing regulator of the present invention comprises a continuous sequence that is completely complementary (ie, 100% complementary) to SEQ ID NO556.

[0128] One aspect of the present invention relates to an antisense oligonucleotide splicing regulator comprising a contiguous nucleotide sequence complementary to SEQ ID NO 557 and having a length of 8 to 40 nucleotides.

[0129] In some embodiments, the antisense oligonucleotide splicing regulator of the present invention comprises a continuous sequence that is at least 90% complementary to SEQ ID NO 557, such as at least 91%, such as at least 92%, such as at least 93%, such as at least 94%, such as at least 95%, such as at least 96%, such as at least 97%, such as at least 98% or 100% complementary.

[0130] In a preferred embodiment, the antisense oligonucleotide splicing regulator of the present invention comprises a contiguous sequence that is completely complementary to SEQ ID NO 557 (ie, 100% complementary).

[0131] One aspect of the present invention relates to an antisense oligonucleotide splicing regulator comprising a contiguous nucleotide sequence complementary to SEQ ID NO 558 and having a length of 8 to 40 nucleotides.

[0132] In some embodiments, the antisense oligonucleotide splicing regulator of the present invention comprises a continuous sequence that is at least 90% complementary to SEQ ID NO 558, such as at least 91%, such as at least 92%, such as at least 93%, such as at least 94%, such as at least 95%, such as at least 96%, such as at least 97%, such as at least 98% or 100% complementary.

[0133] In a preferred embodiment, the antisense oligonucleotide splicing regulator of the present invention comprises a contiguous sequence that is completely complementary to SEQ ID NO 558 (ie, 100% complementary).

[0134] In one embodiment, the target sequence is SEQ ID NO 554. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 554.

[0135] In one embodiment, the target sequence is SEQ ID NO 555. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 555.

[0136] In one embodiment, the target sequence is SEQ ID NO 556. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 556.

[0137] In one embodiment, the target sequence is SEQ ID NO 557. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 557.

[0138] In one embodiment, the target sequence is SEQ ID NO 558. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 558.

[0139] 19, SEQ ID NO 20, SEQ ID NO 21, SEQ ID NO 22, SEQ ID NO 23, SEQ ID NO 24, SEQ ID NO 25, SEQ ID NO 26, SEQ ID NO 27, SEQ ID NO 28, SEQ ID NO 29, SEQ ID NO 30, SEQ ID NO 31, SEQ ID NO 32, SEQ ID NO 33, SEQ ID NO 34, SEQ ID NO 35, SEQ ID NO 36, SEQ ID NO 37, SEQ ID NO 38, SEQ ID NO 39, SEQ ID NO 40, SEQ ID NO 41, SEQ ID NO 42, SEQ ID NO 43, SEQ ID NO 44, SEQ ID NO 45, SEQ ID NO 46, SEQ ID NO 47, SEQ ID NO 48, SEQ ID NO 49, SEQ ID NO 50, SEQ ID NO 51, SEQ ID NO 52, SEQ ID NO 53, SEQ ID NO 54, SEQ ID NO 55 NO33, SEQ ID NO 34, SEQ ID NO 35, SEQ ID NO 36, SEQ ID NO 37, SEQ ID NO 38, SEQ ID NO39, SEQ ID NO 40, SEQ ID NO 41, SEQ ID NO 42, SEQ ID NO 43, SEQ ID NO 44, SEQ ID NO45, SEQ ID NO 46, SEQ ID NO 47, SEQ ID NO 48, SEQ ID NO 49, SEQ ID NO 50, SEQ ID NO 51, SEQ ID NO 52, SEQ ID NO 53, SEQ ID NO 54, SEQ ID NO 55, SEQ ID NO 56, SEQ ID NO 57, SEQ ID NO 58, SEQ ID NO 59, SEQ ID NO 60, SEQ ID NO 61, SEQ ID NO 62, SEQ ID NO63, SEQ ID NO 64, SEQ ID NO 65, SEQ ID NO 66, SEQ ID NO 67, SEQ ID NO 68, SEQ ID NO69, SEQ ID NO 70, SEQ ID NO 71, SEQ ID NO 72, SEQ ID NO 73, SEQ ID NO 74, SEQ ID NO75, SEQ ID NO 76, SEQ IDNO 77、SEQ ID NO 78、SEQ ID NO 79、SEQ ID NO 80、SEQ ID NO81、SEQ ID NO 82、SEQ ID NO 83、SEQ ID NO 84、SEQ ID NO 85、SEQ ID NO 86、SEQ ID NO87、SEQ ID NO 88、SEQ ID NO 89、SEQ ID NO 90、SEQ ID NO 91、SEQ ID NO 92、SEQ ID NO93、SEQ ID NO 94、SEQ ID NO 95、SEQ ID NO 96、SEQ ID NO 97、SEQ ID NO:98、SEQ IDNO:99、SEQ ID NO:100、SEQ ID NO:101、SEQ ID NO:102、SEQ ID NO:103、SEQ ID NO:104、SEQ ID NO:105、SEQ ID NO:106、SEQ ID NO:107、SEQ ID NO:108、SEQ ID NO:109、SEQ IDNO:110、SEQ ID NO:111、SEQ ID NO:112、SEQ ID NO:113、SEQ ID NO:114、SEQ ID NO:115、SEQ ID NO:116、SEQ ID NO:117、SEQ ID NO:118、SEQ ID NO:119、SEQ ID NO:120、SEQ IDNO:121、SEQ ID NO:122、SEQ ID NO:123、SEQ ID NO:124、SEQ ID NO:125、SEQ ID NO:126、SEQ ID NO:127、SEQ ID NO:128、SEQ ID NO:129、SEQ ID NO:130、SEQ ID NO:131、SEQ IDNO:132、SEQ ID NO:133、SEQ ID NO:134、SEQ ID NO:135、SEQ ID NO:136、SEQ ID NO:137、SEQ ID NO:138、SEQ ID NO:139、SEQ ID NO:140、SEQ ID NO:141、SEQ ID NO:142、SEQ IDNO:143、SEQ ID NO:144、SEQ ID NO:145、SEQ ID NO:146、SEQ ID NO:147、SEQ ID NO:148、SEQ ID NO:149、SEQ IDNO:150、SEQ ID NO:151、SEQ ID NO:152、SEQ ID NO:153、SEQ IDNO:154、SEQ ID NO:155、SEQ ID NO:156、SEQ ID NO:157、SEQ ID NO:158、SEQ ID NO:159、SEQ ID NO:160、SEQ ID NO:161、SEQ ID NO:162、SEQ ID NO:163、SEQ ID NO:164、SEQ IDNO:165、SEQ ID NO:166、SEQ ID NO:167、SEQ ID NO:168、SEQ ID NO:169、SEQ ID NO:170、SEQ ID NO:171、SEQ ID NO:172、SEQ ID NO:173、SEQ ID NO:174、SEQ ID NO:175、SEQ IDNO:176、SEQ ID NO:177、SEQ ID NO:178、SEQ ID NO:179、SEQ ID NO:180、SEQ ID NO:181、SEQ ID NO:182、SEQ ID NO:183、SEQ ID NO:184、SEQ ID NO:185、SEQ ID NO:186、SEQ IDNO:187、SEQ ID NO:188、SEQ ID NO:189、SEQ ID NO:190、SEQ ID NO:191、SEQ ID NO:192、SEQ ID NO:193、SEQ ID NO:194、SEQ ID NO:195、SEQ ID NO:196、SEQ ID NO:197、SEQ IDNO:198、SEQ ID NO:199、SEQ ID NO:200、SEQ ID NO:201、SEQ ID NO:202、SEQ ID NO:203、SEQ ID NO:204、SEQ ID NO:205、SEQ ID NO:206、SEQ ID NO:207、SEQ ID NO:208、SEQ IDNO:209、SEQ ID NO:210、SEQ ID NO:211、SEQ ID NO:212、SEQ ID NO:213、SEQ ID NO:214、SEQ ID NO:215、SEQ ID NO:216、SEQ ID NO:217、SEQ ID NO:218、SEQ ID NO:219、SEQ IDNO:220、SEQ ID NO:221、SEQ IDNO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, SEQ ID NO: 233, SEQ ID NO: 234, SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO: 237, SEQ ID NO: 238, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, SEQ ID NO: 243, SEQ ID NO: 244, SEQ ID NO: 245, SEQ ID NO: 246, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, SEQ ID NO: 252, SEQ ID NO: 253, SEQ ID NO: 254, SEQ ID NO: 255, SEQ ID NO: 256, SEQ ID NO: 257, SEQ ID NO: 258, SEQ ID NO: 259, SEQ ID NO: 260, SEQ ID NO: 261, SEQ ID NO: 262, SEQ ID NO: 263, SEQ ID NO: 264, SEQ ID NO: 265, SEQ ID NO: 266, SEQ ID NO: 267, SEQ ID NO: 268, SEQ ID NO: 269, SEQ ID NO: 270, SEQ ID NO: 271, SEQ ID NO: 272, SEQ ID NO: 273, SEQ ID NO: 274, SEQ ID NO: 275, SEQ ID NO: 276, SEQ ID NO: 277, SEQ ID NO: 278 and SEQ ID NO: 279.

[0140] In some embodiments, the target sequence is selected from the group consisting of: SEQ ID NO: 62; SEQ ID NO: 66, SEQ ID NO: 68, SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 76, SEQ ID NO: 112, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 117, SEQ ID NO: 122, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 146, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 178, SEQ ID NO: 179, SEQ ID NO: 183, SEQ ID NO: 187, SEQ ID NO: 189, SEQ ID NO: 192, SEQ ID NO: 193, SEQ ID NO: 214, SEQ ID NO: 247, SEQ ID NO: 252, SEQ ID NO: 254, SEQ ID NO: 258, SEQ ID NO: 273, SEQ ID NO: 276, SEQ ID NO: 277, SEQ ID NO: 278, and SEQ ID NO: 279.: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162 NO: 142, SEQ ID NO: 143, SEQ ID NO: 146, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 178, SEQ ID NO: 179, SEQ ID NO: 183, SEQ ID NO: 187, SEQ ID NO: 189, SEQ ID NO: 192, SEQ ID NO: 193, SEQ ID NO: 214, SEQ ID NO: 247, SEQ ID NO: 252, SEQ ID NO: 254, SEQ ID NO: 258, SEQ ID NO: 273, SEQ ID NO: 276, SEQ ID NO: 277, SEQ ID NO:278 and SEQ ID NO:279.

[0141] In some embodiments, the target sequence is selected from the group consisting of SEQ ID NO: 66, SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 76, SEQ ID NO: 122, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 146, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 154, SEQ ID NO: ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 273, SEQ ID NO: 276, SEQ ID NO: 277 and SEQ ID NO: 279.In other words, in some embodiments, the contiguous nucleic acid is complementary to a sequence selected from the group consisting of SEQ ID NO: 66, SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 76, SEQ ID NO: 122, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 146, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 154, SEQ ID NO: NO: 155, SEQ ID NO: 156, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 273, SEQ ID NO: 276, SEQ ID NO: 277 and SEQ ID NO: 279.

[0142] In one embodiment, the target sequence is SEQ ID NO 66 or a fragment thereof. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 66 or a fragment thereof.

[0143] In another embodiment, the contiguous nucleotide sequence may be completely complementary to SEQ ID NO 66.

[0144] In one embodiment, the target sequence is SEQ ID NO 70 or a fragment thereof. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 70 or a fragment thereof.

[0145] In another embodiment, the contiguous nucleotide sequence may be completely complementary to SEQ ID NO 70.

[0146] In one embodiment, the target sequence is SEQ ID NO 72 or a fragment thereof. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 72 or a fragment thereof.

[0147] In another embodiment, the contiguous nucleotide sequence may be completely complementary to SEQ ID NO 72.

[0148] In one embodiment, the target sequence is SEQ ID NO 73 or a fragment thereof. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 73 or a fragment thereof.

[0149] In another embodiment, the contiguous nucleotide sequence may be completely complementary to SEQ ID NO 73.

[0150] In one embodiment, the target sequence is SEQ ID NO 74 or a fragment thereof. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 74 or a fragment thereof.

[0151] In another embodiment, the contiguous nucleotide sequence may be completely complementary to SEQ ID NO 74.

[0152] In one embodiment, the target sequence is SEQ ID NO 76 or a fragment thereof. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 76 or a fragment thereof.

[0153] In another embodiment, the contiguous nucleotide sequence may be completely complementary to SEQ ID NO 76.

[0154] In one embodiment, the target sequence is SEQ ID NO 122 or a fragment thereof. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 122 or a fragment thereof.

[0155] In another embodiment, the contiguous nucleotide sequence may be completely complementary to SEQ ID NO 122.

[0156] In one embodiment, the target sequence is SEQ ID NO 125 or a fragment thereof. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 125 or a fragment thereof.

[0157] In another embodiment, the contiguous nucleotide sequence may be completely complementary to SEQ ID NO 125.

[0158] In one embodiment, the target sequence is SEQ ID NO 126 or a fragment thereof. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 126 or a fragment thereof.

[0159] In another embodiment, the contiguous nucleotide sequence may be completely complementary to SEQ ID NO 126.

[0160] In one embodiment, the target sequence is SEQ ID NO 127 or a fragment thereof. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 127 or a fragment thereof.

[0161] In another embodiment, the contiguous nucleotide sequence may be completely complementary to SEQ ID NO 127.

[0162] In one embodiment, the target sequence is SEQ ID NO 128 or a fragment thereof. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 128 or a fragment thereof.

[0163] In another embodiment, the contiguous nucleotide sequence may be completely complementary to SEQ ID NO 128.

[0164] In one embodiment, the target sequence is SEQ ID NO 129 or a fragment thereof. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 129 or a fragment thereof.

[0165] In another embodiment, the contiguous nucleotide sequence may be completely complementary to SEQ ID NO 129.

[0166] In one embodiment, the target sequence is SEQ ID NO 130 or a fragment thereof. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 130 or a fragment thereof.

[0167] In another embodiment, the contiguous nucleotide sequence may be completely complementary to SEQ ID NO 130.

[0168] In one embodiment, the target sequence is SEQ ID NO 131 or a fragment thereof. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 131 or a fragment thereof.

[0169] In another embodiment, the contiguous nucleotide sequence may be completely complementary to SEQ ID NO 131.

[0170] In one embodiment, the target sequence is SEQ ID NO 133 or a fragment thereof. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 133 or a fragment thereof.

[0171] In another embodiment, the contiguous nucleotide sequence may be completely complementary to SEQ ID NO 133.

[0172] In one embodiment, the target sequence is SEQ ID NO 134 or a fragment thereof. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 134 or a fragment thereof.

[0173] In another embodiment, the contiguous nucleotide sequence may be completely complementary to SEQ ID NO 134.

[0174] In one embodiment, the target sequence is SEQ ID NO 135 or a fragment thereof. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 135 or a fragment thereof.

[0175] In another embodiment, the contiguous nucleotide sequence may be completely complementary to SEQ ID NO 135.

[0176] In one embodiment, the target sequence is SEQ ID NO 136 or a fragment thereof. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 136 or a fragment thereof.

[0177] In another embodiment, the contiguous nucleotide sequence may be completely complementary to SEQ ID NO 136.

[0178] In one embodiment, the target sequence is SEQ ID NO 138 or a fragment thereof. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 138 or a fragment thereof.

[0179] In another embodiment, the contiguous nucleotide sequence may be completely complementary to SEQ ID NO 138.

[0180] In one embodiment, the target sequence is SEQ ID NO 139 or a fragment thereof. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 139 or a fragment thereof.

[0181] In another embodiment, the contiguous nucleotide sequence may be completely complementary to SEQ ID NO 138.

[0182] In one embodiment, the target sequence is SEQ ID NO 140 or a fragment thereof. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 140 or a fragment thereof.

[0183] In another embodiment, the contiguous nucleotide sequence may be completely complementary to SEQ ID NO 140.

[0184] In one embodiment, the target sequence is SEQ ID NO 141 or a fragment thereof. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 141 or a fragment thereof.

[0185] In another embodiment, the contiguous nucleotide sequence may be completely complementary to SEQ ID NO 141.

[0186] In one embodiment, the target sequence is SEQ ID NO 142 or a fragment thereof. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 142 or a fragment thereof.

[0187] In another embodiment, the contiguous nucleotide sequence may be completely complementary to SEQ ID NO 142.

[0188] In one embodiment, the target sequence is SEQ ID NO 143 or a fragment thereof. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 143 or a fragment thereof.

[0189] In another embodiment, the contiguous nucleotide sequence may be completely complementary to SEQ ID NO 143.

[0190] In one embodiment, the target sequence is SEQ ID NO 146 or a fragment thereof. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 146 or a fragment thereof.

[0191] In another embodiment, the contiguous nucleotide sequence may be completely complementary to SEQ ID NO 146.

[0192] In one embodiment, the target sequence is SEQ ID NO 151 or a fragment thereof. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 151 or a fragment thereof.

[0193] In another embodiment, the contiguous nucleotide sequence may be completely complementary to SEQ ID NO 151.

[0194] In one embodiment, the target sequence is SEQ ID NO 152 or a fragment thereof. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 152 or a fragment thereof.

[0195] In another embodiment, the contiguous nucleotide sequence may be completely complementary to SEQ ID NO 152.

[0196] In one embodiment, the target sequence is SEQ ID NO 154 or a fragment thereof. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 154 or a fragment thereof.

[0197] In another embodiment, the contiguous nucleotide sequence may be completely complementary to SEQ ID NO 154.

[0198] In one embodiment, the target sequence is SEQ ID NO 155 or a fragment thereof. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 155 or a fragment thereof.

[0199] In another embodiment, the contiguous nucleotide sequence may be completely complementary to SEQ ID NO 155.

[0200] In one embodiment, the target sequence is SEQ ID NO 156 or a fragment thereof. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 156 or a fragment thereof.

[0201] In another embodiment, the contiguous nucleotide sequence may be completely complementary to SEQ ID NO 156.

[0202] In one embodiment, the target sequence is SEQ ID NO 162 or a fragment thereof. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 162 or a fragment thereof.

[0203] In another embodiment, the contiguous nucleotide sequence may be completely complementary to SEQ ID NO 162.

[0204] In one embodiment, the target sequence is SEQ ID NO 163 or a fragment thereof. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 163 or a fragment thereof.

[0205] In another embodiment, the contiguous nucleotide sequence may be completely complementary to SEQ ID NO 163.

[0206] In one embodiment, the target sequence is SEQ ID NO 273 or a fragment thereof. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 273 or a fragment thereof.

[0207] In another embodiment, the contiguous nucleotide sequence may be completely complementary to SEQ ID NO 273.

[0208] In one embodiment, the target sequence is SEQ ID NO 276 or a fragment thereof. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 276 or a fragment thereof.

[0209] In another embodiment, the contiguous nucleotide sequence may be completely complementary to SEQ ID NO 276.

[0210] In one embodiment, the target sequence is SEQ ID NO 277 or a fragment thereof. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 277 or a fragment thereof.

[0211] In another embodiment, the contiguous nucleotide sequence may be completely complementary to SEQ ID NO 277.

[0212] In one embodiment, the target sequence is SEQ ID NO 279 or a fragment thereof. In other words, in some embodiments, the contiguous nucleic acid is complementary to SEQ ID NO 279 or a fragment thereof.

[0213] In another embodiment, the contiguous nucleotide sequence may be completely complementary to SEQ ID NO 279.

[0214] In some embodiments, a fragment of any target sequence can be at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, or at least 17 consecutive nucleotides, preferably at least 10 consecutive nucleotides.

[0215] Complementarity

[0216] The term "complementarity" describes the ability of nucleosides / nucleotides to Watson-Crick base pair. Watson-Crick base pairs are guanine (G)-cytosine (C) and adenine (A)-thymine (T) / uracil (U).

[0217] It will be understood that oligonucleotides may contain nucleosides with modified nucleobases, for example 5-methylcytosine is often used in place of cytosine, and thus the term "complementarity" includes Watson Crick base pairing between unmodified and modified nucleobases (see, e.g., Hirao et al., 2012, Accounts of Chemical Research, 45, 2055 and Bergstrom, 2009, Curr. Protoc. Nucleic Acid Chem., 37, 1.4.1).

[0218] As used herein, the term "complementarity percentage" refers to the ratio of nucleotides complementary to a reference sequence (e.g., a target sequence or sequence motif) of a continuous nucleotide sequence in a nucleic acid molecule (e.g., an oligonucleotide) (expressed as a percentage), which spans a continuous nucleotide sequence. Therefore, the number of aligned nucleobases that are complementary (forming Watson Crick base pairs) between the two sequences (when aligned with the oligonucleotide sequences of the target sequence 5'-3' and 3'-5') is divided by the total number of nucleotides in the oligonucleotide and then multiplied by 100 to calculate the percentage of complementarity. In this comparison, nucleobases / nucleotides that are not aligned (forming base pairs) are referred to as mismatches. When calculating the percentage of complementarity of continuous nucleotide sequences, insertions and deletions are not allowed. It should be understood that when determining complementarity, as long as the functional ability of the nucleobases forming Watson Crick base pairing is retained, the chemical modification of the nucleobase is not considered (e.g., when calculating the percentage of complementarity, 5'-methylcytosine is considered to be the same as cytosine).

[0219] In the present invention, the term "complementary" requires that the antisense oligonucleotide splicing regulator or its contiguous nucleotide sequence is at least about 75% complementary, at least about 80% complementary, at least about 85% complementary, at least about 90% complementary or at least about 95% complementary to the target sequence, such as UNC13A pre-mRNA. In some embodiments, the antisense oligonucleotide splicing regulator or a contiguous sequence thereof can be at least about 75%, at least about 76%, at least about 77%, at least about 78%, at least about 79%, at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% complementary to a target sequence, e.g., UNC13A pre-mRNA, or 100% complementary.

[0220] In some embodiments, the antisense oligonucleotide splicing regulators of the invention or contiguous nucleotide sequences thereof may include one, two, three or more mismatches, wherein a mismatch is a nucleotide within the antisense oligonucleotide splicing regulator or contiguous nucleotides thereof that does not base pair with its target.

[0221] The term "fully complementary" refers to 100% complementarity.

[0222] In some embodiments, the antisense oligonucleotide splicing modulator is fully complementary to the target sequence.

[0223] In some embodiments, the contiguous nucleotide sequence is fully complementary to the target sequence.

[0224] Identity

[0225] As used herein, the term "identity" refers to the proportion (expressed as a percentage) of nucleotides in a contiguous nucleotide sequence in a nucleic acid molecule (e.g., an antisense oligonucleotide splicing regulator) that are identical to a reference sequence (e.g., a sequence motif), the nucleic acid molecule spanning the contiguous nucleotide sequence.

[0226] Therefore, the percent identity is calculated by counting the number of aligned nucleobases that are identical (matched) in the two sequences (in the contiguous nucleotide sequence of the antisense oligonucleotide splicing regulator of the present invention and in the reference sequence), dividing the number by the total number of nucleotides in the contiguous nucleotide sequence and multiplying by 100. Therefore, percent identity = (number of matches × 100) / length of the alignment region (e.g., contiguous nucleotide sequence). When calculating the percent identity of a contiguous nucleotide sequence, insertions and deletions are not allowed. It should be understood that when determining identity, chemical modifications of the nucleobases are not considered (e.g., 5-methylcytosine is considered to be the same as cytosine when calculating the percent identity) as long as the functional ability of the nucleobase to form Watson Crick base pairing is retained.

[0227] Thus, it will be appreciated that there is a relationship between identity and complementarity such that a contiguous nucleotide sequence within an antisense oligonucleotide splicing regulator of the invention that is complementary to a target sequence also shares a certain percentage of identity with the target sequence.

[0228] Hybridization

[0229] As used herein, the term "hybridizing" (hybridizing / hybridizes) should be understood as the formation of hydrogen bonds between base pairs on opposite strands of two nucleic acid chains (e.g., an oligonucleotide and a target nucleic acid), thereby forming a duplex. The affinity of the binding between the two nucleic acid chains is the strength of the hybridization. It is usually described by the melting temperature (Tm), which is defined as the temperature at which half of the oligonucleotide forms a duplex with the target nucleic acid. Under physiological conditions, Tm and affinity are not strictly proportional (Mergny and Lacroix, 2003, Oligonucleotides 13: 515-537). The standard state Gibbs free energy ΔG° is a more accurate expression of the binding affinity and is related to the dissociation constant (Kd) of the reaction by ΔG°=-RTln(Kd), where R is the gas constant and T is the absolute temperature. Therefore, a very low ΔG° of the reaction between an oligonucleotide and a target nucleic acid reflects a strong hybridization between the oligonucleotide and the target nucleic acid. ΔG° is the energy associated with a reaction where the aqueous concentration is 1 M, the pH is 7 and the temperature is 37°C. The hybridization of an oligonucleotide to a target nucleic acid is a spontaneous reaction, and for a spontaneous reaction, ΔG° is less than zero. ΔG° can be measured experimentally, for example, by utilizing isothermal titration calorimetry (ITC) methods as described in Hansen et al., 1965, Chem. Comm. 36-38 and Holdgate et al., 2005, Drug Discov Today. Those skilled in the art will know that commercial equipment can be used to measure ΔG°. ΔG° can also be estimated numerically by using the nearest neighbor model as described by SantaLucia, 1998, Proc Natl Acad Sci USA. 95:1460-1465, appropriately using the derived thermodynamic parameters described by Sugimoto et al., 1995, Biochemistry 34:11211-11216 and McTigue et al., 2004, Biochemistry 43:5388-5405.

[0230] In some embodiments, antisense oligonucleotide splicing modulators of the invention hybridize to a target nucleic acid with a ΔG° estimate of less than -10 kcal for oligonucleotides of 10 to 30 nucleotides in length.

[0231] In some embodiments, the degree or strength of hybridization is measured by the standard state Gibbs free energy ΔG °. For oligonucleotides of 8-30 nucleotides in length, antisense oligonucleotide splicing regulators can hybridize with target nucleic acids at a ΔG ° estimate of less than -10 kcal, such as less than -15 kcal, such as less than -20 kcal, and such as less than -25 kcal. In some embodiments, antisense oligonucleotide splicing regulators hybridize with target nucleic acids at a ΔG ° estimate of -10 to -60 kcal, such as -12 to -40, such as -15 to -30 kcal or -16 to -27 kcal, such as -18 to -25 kcal.

[0232] Antisense oligonucleotide splicing modulators

[0233] The antisense oligonucleotide of the present invention is an antisense oligonucleotide splicing regulator comprising a continuous nucleotide sequence complementary to UNC13A pre-mRNA.

[0234] In some embodiments, the continuous nucleotide sequence is a sequence selected from the group consisting of: SEQ ID NO: 280, SEQ ID NO: 281, SEQ ID NO: 282, SEQ ID NO: 283, SEQ ID NO: 284, SEQ ID NO: 285, SEQ ID NO: 286, SEQ ID NO: 287, SEQ ID NO: 288, SEQ ID NO: 289, SEQ ID NO: 290, SEQ ID NO: 291, SEQ ID NO: 292, SEQ ID NO: 293, SEQ ID NO: 294, SEQ ID NO: 295, SEQ ID NO: 296, SEQ ID NO: 297, SEQ ID NO: 298, SEQ ID NO: 299, SEQ ID NO: 300, SEQ ID NO: 301, SEQ ID NO: 302, SEQ ID NO: 303, SEQ ID NO: 304, SEQ ID NO: 305, SEQ ID NO: 306, SEQ ID NO: 307, SEQ ID NO: 308, SEQ ID NO: 309, SEQ ID NO: 310, SEQ ID NO: 311, SEQ ID NO: 312, SEQ ID NO: 313, SEQ ID NO: 314, SEQ ID NO: 315, SEQ ID NO: 316, SEQ ID NO: 317, SEQ ID NO: 318, SEQ ID NO: 319, SEQ ID NO: 320, SEQ ID NO: 321, SEQ ID NO: 322, SEQ ID NO: 323, SEQ ID NO: 324, SEQ ID NO: 325, SEQ ID NO: 326, SEQ ID NO: 327, SEQ ID NO: 328, SEQ ID NO: 329, SEQ ID NO: 330, SEQ ID NO: 331, SEQ ID NO: 332, SEQ ID NO: 333, SEQ ID NO: 334, SEQ ID NO: 335, SEQ ID NO: 336, SEQ ID NO: 337, SEQ ID NO: 338, SEQ ID NO: 339, SEQ ID NO: 340, SEQ ID NO: 341, SEQ ID NO: 342, SEQ ID NO: 343, SEQ ID NO: 344, SEQ ID NO: 345, SEQ ID NO: 346, SEQ ID NO: 347, SEQ ID NO: 348, SEQ IDNO:349、SEQ ID NO:350、SEQ ID NO:351、SEQ ID NO:352、SEQ ID NO:353、SEQ ID NO:354、SEQ ID NO:355、SEQ ID NO:356、SEQ IDNO:357、SEQ ID NO:358、SEQ ID NO:359、SEQ ID NO:360、SEQ ID NO:361、SEQ ID NO:362、SEQ ID NO:363、SEQ ID NO:364、SEQ ID NO:365、SEQ ID NO:366、SEQ ID NO:367、SEQ IDNO:368、SEQ ID NO:369、SEQ ID NO:370、SEQ ID NO:371、SEQ ID NO:372、SEQ ID NO:373、SEQ ID NO:374、SEQ ID NO:375、SEQ ID NO:376、SEQ ID NO:377、SEQ ID NO:378、SEQ IDNO:379、SEQ ID NO:380、SEQ ID NO:381、SEQ ID NO:382、SEQ ID NO:383、SEQ ID NO:384、SEQ ID NO:385、SEQ ID NO:386、SEQ ID NO:387、SEQ ID NO:388、SEQ ID NO:389、SEQ IDNO:390、SEQ ID NO:391、SEQ ID NO:392、SEQ ID NO:393、SEQ ID NO:394、SEQ ID NO:395、SEQ ID NO:396、SEQ ID NO:397、SEQ ID NO:398、SEQ ID NO:399、SEQ ID NO:400、SEQ IDNO:401、SEQ ID NO:402、SEQ ID NO:403、SEQ ID NO:404、SEQ ID NO:405、SEQ ID NO:406、SEQ ID NO:407、SEQ ID NO:408、SEQ ID NO:409、SEQ ID NO:410、SEQ ID NO:411、SEQ IDNO:412、SEQ ID NO:413、SEQ ID NO:414、SEQ ID NO:415、SEQ ID NO:416、SEQ ID NO:417、SEQ ID NO:418、SEQ ID NO:419、SEQ ID NO:420、SEQID NO:421、SEQ ID NO:422、SEQ IDNO:423、SEQ ID NO:424、SEQ ID NO:425、SEQ ID NO:426、SEQ ID NO:427、SEQ ID NO:428、SEQ ID NO:429、SEQ ID NO:430、SEQ ID NO:431、SEQ ID NO:432、SEQ ID NO:433、SEQ IDNO:434、SEQ ID NO:435、SEQ ID NO:436、SEQ ID NO:437、SEQ ID NO:438、SEQ ID NO:439、SEQ ID NO:440、SEQ ID NO:441、SEQ ID NO:442、SEQ ID NO:443、SEQ ID NO:444、SEQ IDNO:445、SEQ ID NO:446、SEQ ID NO:447、SEQ ID NO:448、SEQ ID NO:449、SEQ ID NO:450、SEQ ID NO:451、SEQ ID NO:452、SEQ ID NO:453、SEQ ID NO:454、SEQ ID NO:455、SEQ IDNO:456、SEQ ID NO:457、SEQ ID NO:458、SEQ ID NO:459、SEQ ID NO:460、SEQ ID NO:461、SEQ ID NO:462、SEQ ID NO:463、SEQ ID NO:464、SEQ ID NO:465、SEQ ID NO:466、SEQ IDNO:467、SEQ ID NO:468、SEQ ID NO:469、SEQ ID NO:470、SEQ ID NO:471、SEQ ID NO:472、SEQ ID NO:473、SEQ ID NO:474、SEQ ID NO:475、SEQ ID NO:476、SEQ ID NO:477、SEQ IDNO:478、SEQ ID NO:479、SEQ ID NO:480、SEQ ID NO:481、SEQ ID NO:482、SEQ ID NO:483、SEQ ID NO:484、SEQ ID NO:485、SEQ ID NO:486、SEQ ID NO:487、SEQ ID NO:488、SEQ IDNO:489、SEQ ID NO:490、SEQ ID NO:491、SEQ ID NO:492、SEQID NO: 493, SEQ ID NO: 494, SEQ ID NO: 495, SEQ ID NO: 496, SEQ ID NO: 497, SEQ ID NO: 498, SEQ ID NO: 499, SEQ ID NO: 500, SEQ ID NO: 501, SEQ ID NO: 502, SEQ ID NO: 503, SEQ ID NO: 504, SEQ ID NO: 505, SEQ ID NO: 506, SEQ ID NO: 507, SEQ ID NO: 508, SEQ ID NO: 509, SEQ ID NO: 510, SEQ ID NO: 511, SEQ ID NO: 512, SEQ ID NO: 513, SEQ ID NO: 514, SEQ ID NO: 515, SEQ ID NO: 516, SEQ ID NO: 517, SEQ ID NO: 518, SEQ ID NO: 519, SEQ ID NO: 520, SEQ ID NO: 521, SEQ ID NO: 522, SEQ ID NO: 523, SEQ ID NO: 524, SEQ ID NO: 525, SEQ ID NO: 526, SEQ ID NO: 527, SEQ ID NO: 528, SEQ ID NO: 529, SEQ ID NO: 530, SEQ ID NO: 531, SEQ ID NO: 532, SEQ ID NO: 533, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, SEQ ID NO: 541, SEQ ID NO: 542, SEQ ID NO: 543, SEQ ID NO: 544, SEQ ID NO: 545, SEQ ID NO: 546, SEQ ID NO: 547, SEQ ID NO: 548, SEQ ID NO:549, SEQ ID NO:550 and SEQ ID NO:551, or fragments thereof.

[0235] In some embodiments, a fragment can be at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, or at least 17 consecutive nucleotides of a consecutive nucleotide sequence, preferably at least 10 consecutive nucleotides.

[0236] In some embodiments, the contiguous nucleotide sequence is a sequence selected from the group consisting of SEQ ID NO: 334; SEQ ID NO: 338; SEQ ID NO: 340; SEQ ID NO: 342; SEQ ID NO: 344; SEQ ID NO: 345; SEQ ID NO: 346; SEQ ID NO: 348; SEQ ID NO: 384; SEQ ID NO: 386; SEQ ID NO: 387; SEQ ID NO: 389; SEQ ID NO: 394; SEQ ID NO: 397; SEQ ID NO: 398; SEQ ID NO: 399; SEQ ID NO: 400; SEQ ID NO: 401; SEQ ID NO: 402; SEQ ID NO: 403; SEQ ID NO: 405; SEQ ID NO: 406; SEQ ID NO: 407; SEQ ID NO: 408; SEQ ID NO: 409; SEQ ID NO: 410; SEQ ID NO: 411; SEQ ID NO: 412; SEQ ID NO: 413; SEQ ID NO: 414; SEQ ID NO: 415 SEQ ID NO:414; SEQ ID NO:415; SEQ ID NO:418; SEQ ID NO:423; SEQ ID NO:424; SEQ ID NO:425; SEQ ID NO:426, SEQ ID NO:427, SEQ ID NO:428, SEQ ID NO:434, SEQ ID NO:435, SEQ ID NO:450, SEQ ID NO: 451, SEQ ID NO: 455, SEQ ID NO: 459, SEQ ID NO: 461, SEQ ID NO: 464, SEQ ID NO: 465, SEQ ID NO: 486, SEQ ID NO: 519, SEQ ID NO: 524, SEQ ID NO: 526, SEQ ID NO: 530, SEQ ID NO: 545, SEQ ID NO: 548, SEQ ID NO:549, SEQ ID NO:550 and SEQ ID NO:551, or fragments thereof.

[0237] In some embodiments, a fragment can be at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, or at least 17 consecutive nucleotides of a consecutive nucleotide sequence, preferably at least 10 consecutive nucleotides.

[0238] In some embodiments, the contiguous nucleotide sequence is a sequence selected from the group consisting of SEQ ID NO: 338, SEQ ID NO: 342, SEQ ID NO: 344, SEQ ID NO: 345, SEQ ID NO: 346, SEQ ID NO: 348, SEQ ID NO: 394, SEQ ID NO: 397, SEQ ID NO: 398, SEQ ID NO: 399, SEQ ID NO: 400, SEQ ID NO: 401, SEQ ID NO: 402, SEQ ID NO: 403, SEQ ID NO: 405, SEQ ID NO: 406, SEQ ID NO: 407, SEQ ID NO: 408, SEQ ID NO: 409, SEQ ID NO: 410, SEQ ID NO: 411, SEQ ID NO: 412, SEQ ID NO: 413, SEQ ID NO: 414, SEQ ID NO: 415, SEQ ID NO: 418, SEQ ID NO: 423, SEQ ID NO: 424, SEQ ID NO: NO:426, SEQ ID NO:427, SEQ ID NO:428, SEQ ID NO:434, SEQ ID NO:435, SEQ ID NO:545, SEQ ID NO:548, SEQ ID NO:549 and SEQ ID NO:551, or fragments thereof.

[0239] In some embodiments, a fragment can be at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, or at least 17 consecutive nucleotides of a consecutive nucleotide sequence, preferably at least 10 consecutive nucleotides.

[0240] In one embodiment, the contiguous nucleotide sequence comprises SEQ ID NO 338 or a fragment thereof.

[0241] In one embodiment, the contiguous nucleotide sequence comprises SEQ ID NO 342 or a fragment thereof.

[0242] In one embodiment, the contiguous nucleotide sequence comprises SEQ ID NO 344 or a fragment thereof.

[0243] In one embodiment, the contiguous nucleotide sequence comprises SEQ ID NO 345 or a fragment thereof.

[0244] In one embodiment, the contiguous nucleotide sequence comprises SEQ ID NO 346 or a fragment thereof.

[0245] In one embodiment, the contiguous nucleotide sequence comprises SEQ ID NO 348 or a fragment thereof.

[0246] In one embodiment, the contiguous nucleotide sequence comprises SEQ ID NO 394 or a fragment thereof.

[0247] In one embodiment, the contiguous nucleotide sequence comprises SEQ ID NO 397 or a fragment thereof.

[0248] In one embodiment, the contiguous nucleotide sequence comprises SEQ ID NO 398 or a fragment thereof.

[0249] In one embodiment, the contiguous nucleotide sequence comprises SEQ ID NO 399 or a fragment thereof.

[0250] In one embodiment, the contiguous nucleotide sequence comprises SEQ ID NO 400 or a fragment thereof.

[0251] In one embodiment, the contiguous nucleotide sequence comprises SEQ ID NO 401 or a fragment thereof.

[0252] In one embodiment, the contiguous nucleotide sequence comprises SEQ ID NO 402 or a fragment thereof.

[0253] In one embodiment, the contiguous nucleotide sequence comprises SEQ ID NO 403 or a fragment thereof.

[0254] In one embodiment, the contiguous nucleotide sequence comprises SEQ ID NO 405 or a fragment thereof.

[0255] In one embodiment, the contiguous nucleotide sequence comprises SEQ ID NO 406 or a fragment thereof.

[0256] In one embodiment, the contiguous nucleotide sequence comprises SEQ ID NO 407 or a fragment thereof.

[0257] In one embodiment, the contiguous nucleotide sequence comprises SEQ ID NO 408 or a fragment thereof.

[0258] In one embodiment, the contiguous nucleotide sequence comprises SEQ ID NO 409 or a fragment thereof.

[0259] In one embodiment, the contiguous nucleotide sequence comprises SEQ ID NO 410 or a fragment thereof.

[0260] In one embodiment, the contiguous nucleotide sequence comprises SEQ ID NO 411 or a fragment thereof.

[0261] In one embodiment, the contiguous nucleotide sequence comprises SEQ ID NO 412 or a fragment thereof.

[0262] In one embodiment, the contiguous nucleotide sequence comprises SEQ ID NO 413 or a fragment thereof.

[0263] In one embodiment, the contiguous nucleotide sequence comprises SEQ ID NO 414 or a fragment thereof.

[0264] In one embodiment, the contiguous nucleotide sequence comprises SEQ ID NO 415 or a fragment thereof.

[0265] In one embodiment, the contiguous nucleotide sequence comprises SEQ ID NO 418 or a fragment thereof.

[0266] In one embodiment, the contiguous nucleotide sequence comprises SEQ ID NO 423 or a fragment thereof.

[0267] In one embodiment, the contiguous nucleotide sequence comprises SEQ ID NO 424 or a fragment thereof.

[0268] In one embodiment, the contiguous nucleotide sequence comprises SEQ ID NO 426 or a fragment thereof.

[0269] In one embodiment, the contiguous nucleotide sequence comprises SEQ ID NO 427 or a fragment thereof.

[0270] In one embodiment, the contiguous nucleotide sequence comprises SEQ ID NO 428 or a fragment thereof.

[0271] In one embodiment, the contiguous nucleotide sequence comprises SEQ ID NO 434 or a fragment thereof.

[0272] In one embodiment, the contiguous nucleotide sequence comprises SEQ ID NO 435 or a fragment thereof.

[0273] In one embodiment, the contiguous nucleotide sequence comprises SEQ ID NO 545 or a fragment thereof.

[0274] In one embodiment, the contiguous nucleotide sequence comprises SEQ ID NO 548 or a fragment thereof.

[0275] In one embodiment, the contiguous nucleotide sequence comprises SEQ ID NO 549 or a fragment thereof.

[0276] In one embodiment, the contiguous nucleotide sequence comprises SEQ ID NO 551 or a fragment thereof.

[0277] In some embodiments, a fragment can be at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, or at least 17 consecutive nucleotides of a consecutive nucleotide sequence, preferably at least 10 consecutive nucleotides.

[0278] Nucleotides and nucleosides

[0279] Nucleotides and nucleosides are components of oligonucleotides and polynucleotides, and for purposes of the present invention, include naturally occurring and non-naturally occurring nucleotides and nucleosides. In nature, nucleotides, such as DNA and RNA nucleotides, contain a ribose sugar moiety, a core base moiety, and one or more phosphate groups (which are not present in nucleosides). Nucleosides and nucleotides may also be referred to interchangeably as "units" or "monomers."

[0280] Modified Nucleosides

[0281] As used herein, the term "modified nucleoside" or "nucleoside modification" refers to a nucleoside that has been modified compared to the equivalent DNA or RNA nucleoside by the introduction of one or more modifications to the sugar moiety or the (nucleo)base moiety.

[0282] Advantageously, the antisense oligonucleotide splicing modulators according to the invention may comprise one or more modified nucleosides.

[0283] In some embodiments, the antisense oligonucleotide splicing regulator or its contiguous nucleotide sequence (motif sequence) may be modified, for example, to increase nuclease resistance and / or binding affinity to the target nucleic acid. Advantageously, high affinity modified nucleosides are used.

[0284] Advantageously, one or more modified nucleosides of the antisense oligonucleotide splicing regulator according to the present invention may include a modified sugar moiety. The term modified nucleosides may also be used interchangeably with the term "nucleoside analogs" or modified "units" or modified "monomers" herein. Nucleosides with unmodified DNA or RNA sugar moieties are referred to herein as DNA or RNA nucleosides. If Watson Crick (Watson Crick) base pairing is allowed in the base region of a DNA or RNA nucleoside, it is still generally referred to as DNA or RNA. Exemplary modified nucleosides that can be used in the antisense oligonucleotide splicing regulator according to the present invention include LNA, 2'-O-MOE, 2'oMe and morpholino nucleoside analogs.

[0285] Modified internucleoside linkages

[0286] Advantageously, the antisense oligonucleotide splicing modulators according to the invention comprise one or more modified internucleoside linkages.

[0287] As is generally understood by the skilled artisan, the term "modified internucleoside linkage" is defined as a linkage other than a phosphodiester (PO) linkage that covalently couples two nucleosides together. Thus, the antisense oligonucleotide splicing modulators of the invention may comprise one or more modified internucleoside linkages, such as one or more phosphorothioate internucleoside linkages.

[0288] In some embodiments, at least 50% of the internucleoside bonds in the antisense oligonucleotide splicing regulator or its contiguous nucleotide sequence according to the present invention are phosphorothioate, such as at least 60%, such as at least 70%, such as at least 75%, such as at least 80%, such as at least 90% or more of the internucleoside bonds in the antisense oligonucleotide or its contiguous nucleotide sequence are phosphorothioate. In some embodiments, all internucleoside bonds in the antisense oligonucleotide splicing regulator or its contiguous nucleotide sequence of the present invention are phosphorothioate.

[0289] In a further embodiment, the antisense oligonucleotide splicing regulator or its contiguous nucleotide sequence according to the invention comprises at least one modified internucleoside bond. It is advantageous if at least 75%, such as all, of the internucleoside bonds within the contiguous nucleotide sequence are phosphorothioate or boranophosphate internucleoside bonds.

[0290] Advantageously, all internucleoside bonds of the contiguous nucleotide sequence of the antisense oligonucleotide splicing regulator according to the present invention may be phosphorothioate bonds, or all internucleoside bonds of the antisense oligonucleotide splicing regulator according to the present invention may be phosphorothioate bonds.

[0291] Nucleobase

[0292] The term nucleobase includes purines (e.g., adenine and guanine) and pyrimidines (e.g., uracil, thymine, and cytosine) present in nucleosides and nucleotides, which form hydrogen bonds in nucleic acid hybridization. In the context of the present invention, the term "nucleobase" also includes modified nucleobases, which may be different from naturally occurring nucleobases, but are functional in the nucleic acid hybridization process. In this context, "nucleobase" refers to naturally occurring nucleobases, such as adenine, guanine, cytosine, thymidine, uracil, xanthine, and hypoxanthine, as well as non-naturally occurring variants. Such variants are described, for example, in Hirao et al. (2012) Accounts of Chemical Research, Vol. 45, p. 2055 and Bergstrom (2009) Current Protocols in Nucleic Acid Chemistry Supplement 37 1.4.1.

[0293] In some embodiments, the nucleobase moiety is modified by changing a purine or pyrimidine to a modified purine or pyrimidine, such as a substituted purine or substituted pyrimidine, such as a nucleobase selected from isocytosine, pseudoisocytosine, 5-methylcytosine, 5-thiazolo-cytosine, 5-propynyl-cytosine, 5-propynyl-uracil, 5-bromouracil, 5-thiazolo-uracil, 2-thio-uracil, 2′-thio-thymine, inosine, diaminopurine, 6-aminopurine, 2-aminopurine, 2,6-diaminopurine, and 2-chloro-6-aminopurine.

[0294] The nucleobase moiety can be represented by the letter code of each corresponding nucleobase, such as A, T, G, C or U, wherein each letter can optionally include a modified nucleobase with equivalent function. For example, in an exemplary oligonucleotide, the nucleobase moiety is selected from A, T, G, C and 5-methylcytosine.

[0295] Modified oligonucleotides

[0296] The antisense oligonucleotide splicing regulator of the present invention may be a modified oligonucleotide.

[0297] The term "modified oligonucleotide" describes an oligonucleotide comprising one or more sugar-modified nucleosides and / or modified internucleoside bonds. The term "chimeric oligonucleotide" is a term that has been used in the literature to describe an oligonucleotide comprising sugar-modified nucleosides and DNA nucleosides. In some embodiments, it may be advantageous that the antisense oligonucleotide splicing regulator according to the present invention is or comprises a chimeric oligonucleotide.

[0298] In some embodiments, the antisense oligonucleotide splicing regulators or contiguous nucleotide sequences thereof according to the invention may include modified nucleobases that act as the indicated nucleobases in base pairing, for example, 5-methylcytosine may be used instead of methylcytosine. Inosine may be used as a universal base.

[0299] It will be appreciated that the contiguous nucleobase sequence (motif sequence) may be modified, for example, to increase nuclease resistance and / or binding affinity to a target nucleic acid.

[0300] The pattern of incorporating modified nucleosides, such as high affinity modified nucleosides, into an oligonucleotide sequence is often referred to as oligonucleotide design.

[0301] In an embodiment, the antisense oligonucleotide splicing regulator according to the invention comprises at least 1 modified nucleoside, such as at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18 or at least 19 modified nucleosides.

[0302] Suitable modifications are described herein under the headings "Modified Nucleosides", "High Affinity Modified Nucleosides", "Sugar Modifications", "2' Sugar Modifications" and "Locked Nucleic Acids (LNA)".

[0303] High affinity modified nucleosides

[0304] A high affinity modified nucleoside is a modified nucleoside that, when incorporated into an oligonucleotide, enhances the affinity of the oligonucleotide for its complementary target, as measured, for example, by melting temperature (Tm). The high affinity modified nucleosides of the present invention preferably increase the melting temperature of each modified nucleoside by between +0.5°C and +12°C, more preferably between +1.5°C and +10°C, and most preferably between +3°C and +8°C. Many high affinity modified nucleosides are known in the art, and include, for example, many 2' substituted nucleosides and locked nucleic acids (LNA) (see, for example, Freier & Altmann; Nucl. Acid Res., 1997, 25, 4429-4443 and Uhhnann; Curr. Opinion in Drug Development, 2000, 3(2), 203-213).

[0305] Sugar modification

[0306] Antisense oligonucleotide splicing modulators according to the invention may comprise one or more nucleosides having a modified sugar moiety (ie, a modification of the sugar moiety) when compared to the ribose moiety found in DNA and RNA.

[0307] A number of modified nucleosides having a ribose sugar moiety have been prepared, primarily with the goal of improving certain properties of the oligonucleotide, such as affinity and / or nuclease resistance.

[0308] The present invention relates to the modification of the present invention.These modifications include such modifications, wherein the ribose ring structure is modified, for example, substituted by a hexose ring (HNA) or a dicyclo, which usually has a dicyclo of a diradicle bridge (biradicle bridge) between the C2 and C4 carbon atoms on the ribose ring (LNA), or usually lacks the unconnected ribose ring (for example UNA) of a key between the C2 and C3 carbon atoms.Other sugar-modified nucleosides include, for example, dicyclohexose nucleic acid (WO2011 / 017521) or tricyclic nucleic acid (WO2013 / 154798).The nucleosides of modification also include nucleosides wherein the sugar moiety is replaced by a non-sugar moiety, for example, in the case of peptide nucleic acid (PNA) or morpholino nucleic acid.

[0309] Sugar modifications also include modifications by changing the substituents on the ribose ring to groups other than hydrogen or the 2'-OH group naturally present in DNA and RNA nucleosides. For example, substituents can be introduced at the 2', 3', 4' or 5' positions.

[0310] 2′ sugar-modified nucleosides

[0311] A 2' sugar modified nucleoside is a nucleoside that has a substituent other than H or -OH at the 2' position (2' substituted nucleosides) or contains a 2' linked diradical capable of forming a bridge between the 2' carbon and the second carbon atom in the ribose ring, such as an LNA (2'-4' diradical bridged) nucleoside.

[0312] In fact, people have spent a lot of effort to develop 2' sugar substituted nucleosides, and found that many 2' substituted nucleosides have beneficial properties after incorporation into oligonucleotides. For example, 2' modified sugars can provide enhanced binding affinity and / or increased nuclease resistance to oligonucleotides. Examples of 2' substituted modified nucleosides are 2'-O-alkyl-RNA, 2'-O-methyl-RNA (2'oMe), 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA (MOE), 2'-amino-DNA, 2'-fluoro-RNA and 2'-F-ANA nucleosides. For further examples, see, for example, Freier & Altmann; Nucl. Acid Res., 1997, 25, 4429-4443 and Uhhnann; Curr. Opinion in Drug Development, 2000, 3(2), 203-213 and Deleavey and Damha, Chemistry and Biology 2012, 19, 937. Below are schematic diagrams of some 2' substituted modified nucleosides.

[0313]

[0314] With respect to the present invention, 2' substituted sugar modified nucleosides do not include 2' bridged nucleosides like LNA.

[0315] In one embodiment, the antisense oligonucleotide splicing regulator according to the present invention may comprise one or more sugar-modified nucleosides, such as 2' sugar-modified nucleosides. Preferably, the antisense oligonucleotide splicing regulator according to the present invention comprises one or more 2' sugar-modified nucleosides, which are independently selected from the group consisting of the following items: 2'-O-alkyl-RNA, 2'-O-methyl-RNA (2'oMe), 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA (2'MOE), 2'-amino-DNA, 2'-fluoro-DNA, arabino nucleic acid (ANA), 2'-fluoro-ANA and LNA nucleosides. It is preferred if one or more modified nucleosides are locked nucleic acids (LNA).

[0316] Locked Nucleoside Nucleosides (LNA Nucleosides)

[0317] "LNA nucleosides" are 2'-modified nucleosides that contain a double radical (also called a "2'-4' bridge") connecting the C2' and C4' ribose sugar rings of the nucleoside, which restricts or locks the conformation of the ribose ring. These nucleosides are also referred to in the literature as bridged nucleic acids or bicyclic nucleic acids (BNA). When LNA is incorporated into an oligonucleotide complementary to an RNA or DNA molecule, the locking of the ribose conformation is associated with an enhancement of hybridization affinity (duplex stabilization). This can be routinely determined by measuring the melting temperature of the oligonucleotide / complementary duplex.

[0318] Non-limiting exemplary LNA nucleosides are disclosed in WO 99 / 014226, WO 00 / 66604, WO 98 / 039352, WO 2004 / 046160, WO 00 / 047599, WO 2007 / 134181, WO 2010 / 077578, WO 2010 / 036698, WO 2007 / 090071, WO 2009 / 006478, WO 2011 / 156202, WO 2008 / 154401, WO 2009 / 067647, WO2008 / 150729, Morita et al., Bioorganic & Med. Chem. Lett. 12, 73-76, Seth et al. J. Org. Chem. 2010, Vol. 75(5), pp. 1569-81, and Mitsuoka et al., Nucleic Acids Research 2009, 37(4), 1225-1238, and Wan and Seth, J. Medical Chernistry 2016, 59, 9645-9667.

[0319] Other non-limiting exemplary LNA nucleosides are disclosed in Scheme 1.

[0320] Scenario 1:

[0321]

[0322] Particular LNA nucleosides are β-D-oxy-LNA, 6'-methyl-β-D-oxy-LNA such as (S)-6'-methyl-β-D-oxy-LNA (ScET) and ENA.

[0323] A particularly advantageous LNA is β-D-oxy-LNA.

[0324] Morpholino oligonucleotides

[0325] In some embodiments, the antisense oligonucleotide splicing regulators of the invention comprise or consist of morpholino nucleosides (i.e., morpholino oligomers and phosphorodiamidate morpholino oligomers (PMOs)). Splicing regulating morpholino oligonucleotides have been approved for clinical use - see, for example, eteplirsen, a 30-nucleotide morpholino oligonucleotide targeting a frameshift mutation in DMD, for the treatment of Duchenne muscular dystrophy. Morpholino oligonucleotides have a nuclease attached to a six-membered morpholine ring instead of a ribose, such as a methylene morpholine ring connected by a phosphorodiamidate group, for example, as illustrated by the following 4 consecutive morpholino nucleotides:

[0326]

[0327] In some embodiments, the antisense oligonucleotide splicing regulators according to the invention may be, for example, 8 to 40 morpholino nucleotides in length, such as 16 to 20 morpholino nucleotides in length, such as 18 to 20 morpholino nucleotides in length.

[0328] RNase H activity and recruitment

[0329] The RNase H activity of an antisense oligonucleotide refers to its ability to recruit RNase H when forming a duplex with a complementary RNA molecule. WO01 / 23613 provides an in vitro method for determining RNase H activity, which can be used to determine the ability to recruit RNase H. If an oligonucleotide has an initial rate (in pmol / l / min) when providing a complementary target nucleic acid sequence that is at least 5%, such as at least 10%, at least 20%, or more than 20% of the initial rate determined when using an oligonucleotide having the same base sequence as the modified oligonucleotide being tested but only comprising DNA monomers having phosphorothioate bonds between all monomers in the oligonucleotide and using the methods provided by Examples 91 to 95 of WO01 / 23613 (incorporated herein by reference), then the oligonucleotide is generally considered to be able to recruit RNase H. For use in determining RNase H activity, recombinant RNase H1 can be obtained from LubioSciencee GmbH (Lucerne, Switzerland).

[0330] It is known that DNA oligonucleotides can effectively recruit RNase H, as do gapmer oligonucleotides, which comprise a region of DNA nucleosides (usually at least 5 or 6 consecutive DNA nucleosides) flanked 5' and 3' by regions comprising 2' sugar-modified nucleosides (usually high affinity 2' sugar-modified nucleosides, such as 2-O-MOE and / or LNA). In order to effectively function as a splicing regulator, degradation of pre-mRNA is undesirable, and therefore, preferably, RNase H degradation of the target is avoided. Therefore, the antisense oligonucleotide splicing regulator of the present invention is preferably not an RNase H recruiting gapmer oligonucleotide.

[0331] RNase H recruitment can be avoided by limiting the number of consecutive DNA nucleotides in the antisense oligonucleotide splicing regulator, so mixed polymer and full polymer designs can be used. Advantageously, in some embodiments, the antisense oligonucleotide splicing regulator of the present invention or its consecutive nucleotide sequence does not contain more than 3 consecutive DNA nucleosides. Further, advantageously, in some embodiments, the antisense oligonucleotide splicing regulator of the present invention or its consecutive nucleotide sequence does not contain more than 4 consecutive DNA nucleosides. Further, advantageously, in some embodiments, the antisense oligonucleotide splicing regulator of the present invention or its consecutive nucleotide sequence does not contain more than 2 consecutive DNA nucleosides.

[0332] Polymers and polymers

[0333] In order to be used as a splicing regulator, it is generally advantageous to use an antisense oligonucleotide that does not raise RNAase H and does not cause target precursor-RNA destruction. Because the RNA enzyme H activity requires a continuous sequence of DNA nucleotides, therefore, RNA enzyme H recruitment can be prevented by designing an oligonucleotide that does not include more than 3 or more than 4 continuous DNA nucleosides. This can be achieved by using an antisense oligonucleotide or its continuous nucleoside region (which includes sugar-modified nucleosides, such as 2' sugar-modified nucleosides) and a short DNA nucleoside region (such as 1, 2 or 3 DNA nucleosides) with a mixed polymer design. Mixed polymers are illustrated in this article by "every two" design (wherein nucleosides alternate between 1 LNA and 1 DNA nucleosides, such as LDLDLDLDLDLDLDLL, with 5' end and 3' end LNA nucleosides) and "every three" design (such as LDDLDDLDDLDDLDDL, wherein every three nucleosides are LNA nucleosides).

[0334] In one embodiment, the mixed polymer may comprise or consist of nucleosides alternating between 1, 2 or 3 consecutive DNA nucleosides followed by 1 or 2 consecutive LNA nucleosides.

[0335] A holopolymer is an oligonucleotide or a contiguous nucleotide sequence thereof that does not contain DNA or RNA nucleosides, and may, for example, contain only 2′-O-MOE nucleosides, such as complete MOE phosphorothioate, e.g., MMMMMMMMMMMMMMMMMMMM, where M=2′-O-MOE, or may, for example, contain only 2′oMe nucleosides, which are reported to be effective for therapeutic use.

[0336] Alternatively, the miscellaneous polymer may comprise a mixture of modified nucleosides, such as MLMLMLMLMLMLMLMLMLMLML, where L = LNA and M = 2'-O-MOE nucleoside.

[0337] Advantageously, the internucleoside nucleoside linkages in the mixed and full polymers or the majority of the nucleoside linkages in the mixed polymers may be phosphorothioate.

[0338] Mixed and full polymers may contain other internucleoside linkages, such as phosphodiester or phosphorothioate (as examples).

[0339] In some embodiments, the antisense oligonucleotide splicing regulator is or comprises an oligonucleotide mixed polymer or a full polymer. In some embodiments, the contiguous nucleotide sequence is a mixed polymer or a full polymer.

[0340] Region D' or D" in an oligonucleotide

[0341] In some embodiments, the antisense oligonucleotide splicing regulators of the present invention may comprise a continuous nucleotide sequence of oligonucleotides and additional 5' and / or 3' nucleosides, the continuous nucleotide sequence of these oligonucleotides being complementary to the target nucleic acid (such as a mixed or full polymer region). The other 5' and / or 3' nucleosides may be complementary to the target nucleic acid or may not be complementary (such as fully complementary). Such other 5' and / or 3' nucleosides may be referred to herein as regions D' and D".

[0342] For the purpose of joining a contiguous nucleotide sequence (such as a mixed polymer or a full polymer) to a conjugate moiety or another functional group, an added region D′ or D″ may be used. When used to join a contiguous nucleotide sequence to a conjugate moiety, it may be used as a biocleavable linker. Alternatively, it may be used to provide exonuclease protection or to facilitate synthesis or manufacturing.

[0343] Region D′ or D″ may independently comprise or consist of 1, 2, 3, 4 or 5 additional nucleotides, which may be complementary or non-complementary to the target nucleic acid. The nucleotides adjacent to the F or F′ region are not sugar-modified nucleotides, such as DNA or RNA or base-modified forms of these. The D′ or D″ region may be used as a nuclease-sensitive biocleavable linker (see definition of linker). In some embodiments, the additional 5′ and / or 3′ terminal nucleotides are linked with phosphodiester bonds and are DNA or RNA. Nucleotide-based biocleavable linkers suitable for use as region D′ or D″ are disclosed in WO2014 / 076195, including, for example, phosphodiester-linked DNA dinucleotides. WO2015 / 113922 discloses the use of biocleavable linkers in poly-oligonucleotide constructs, wherein they are used to link multiple antisense constructs within a single oligonucleotide.

[0344] In one embodiment, the antisense oligonucleotide splicing regulator of the present invention may further comprise region D' and / or D" in addition to the continuous nucleotide sequence that can constitute a mixed polymer or a full polymer.

[0345] In some embodiments, the internucleoside bond between region D' or D" and the mixed or full polymer region may be a phosphodiester bond.

[0346] Conjugation

[0347] The present invention encompasses an antisense oligonucleotide splicing regulator covalently linked to at least one conjugate moiety. In some embodiments, it may be referred to as a conjugate of the present invention.

[0348] In some embodiments, the present invention provides an antisense oligonucleotide splicing modulator covalently linked to at least one conjugate moiety.

[0349] As used herein, the term "conjugate" refers to an antisense oligonucleotide splicing regulator covalently linked to a non-nucleotide portion (conjugate portion or region C or third region). The conjugate portion can be covalently linked to the antisense oligonucleotide splicing regulator, optionally via a linker (such as region D' or D ") group.

[0350] Oligonucleotide conjugates and their synthesis are also reviewed by Manoharan in Antisense Drug Technology, Principles, Strategies, and Applications, ST Crooke, ed., Chapter 16, Marcel Dekker, Inc., 2001 and reported in Manoharan, Antisense and Nucleic Acid Drug Development, 2002, 12, 103.

[0351] In some embodiments, the non-nucleotide moiety (conjugate moiety) is selected from the group consisting of carbohydrates (e.g., GalNAc), cell surface receptor ligands, drugs, hormones, lipophilic substances, polymers, proteins, peptides, toxins (e.g., bacterial toxins), vitamins, viral proteins (e.g., capsids), or a combination thereof.

[0352] Connectors

[0353] A bond or linker is a connection between two atoms that connects one target chemical group or segment to another target chemical group or segment via one or more covalent bonds. The conjugate portion can be connected to the antisense oligonucleotide splicing regulator directly or through a connecting portion (e.g., a linker or tether). The linker is used to covalently link a third region, such as a conjugate portion (region C), to a first region, such as an antisense oligonucleotide splicing regulator or a continuous nucleotide sequence (region A) that is complementary to the target nucleic acid.

[0354] In some embodiments of the present invention, the conjugates or antisense oligonucleotide splicing regulators of the present invention may optionally include a linker region (second region or region B and / or region Y) located between the antisense oligonucleotide splicing regulator or the contiguous nucleotide sequence (region A or first region) complementary to the target nucleic acid and the conjugate portion (region C or third region).

[0355] Region B refers to a biodegradable linker comprising or consisting of a physiologically unstable bond that is cleavable under conditions commonly encountered in mammals or under conditions similar thereto. The conditions under which the physiologically unstable linker undergoes chemical transformation (e.g., cleavage) include chemical conditions such as pH, temperature, oxidation or reduction conditions or reagents, and salt concentrations encountered in mammalian cells or salt concentrations similar thereto. Conditions within mammalian cells also include enzyme activities that are commonly present in mammalian cells, such as enzyme activities from proteases or hydrolases or nucleases. In one embodiment, the biodegradable linker is sensitive to S1 nuclease cleavage. In some embodiments, the nuclease-sensitive linker comprises 1 to 5 nucleosides, such as one or more DNA nucleosides comprising at least two consecutive phosphodiester bonds. For a detailed description of the phosphodiester comprising a biodegradable linker, please refer to WO 2014 / 076195.

[0356] Region Y refers to a linker that is not necessarily biocleavable but is primarily used to covalently link the conjugate portion (region C or the third region) to the oligonucleotide (region A or the first region). The region Y linker may comprise a chain structure or oligomer of repeating units such as ethylene glycol, amino acid units or aminoalkyl groups. The antisense oligonucleotide splicing regulator conjugates of the present invention may be composed of the following regional elements AC, ABC, ABYC, AYBC or AYC. In some embodiments, the linker (region Y) is an aminoalkyl group (such as a C2-C36 aminoalkyl group), including, for example, a C6 to C12 aminoalkyl group. In some embodiments, the linker (region Y) is a C6 aminoalkyl group.

[0357] Salt

[0358] The term "salt" as used herein conforms to its commonly known meaning, ie, an ionic assembly of an anion and a cation.

[0359] In some embodiments, the antisense oligonucleotide splicing regulators of the present invention may be in the form of a pharmaceutically acceptable salt. In other words, the present invention provides a pharmaceutically acceptable salt of the antisense oligonucleotide splicing regulators of the present invention.

[0360] In some embodiments, the pharmaceutically acceptable salt may be a sodium salt or a potassium salt.

[0361] The present invention provides a pharmaceutically acceptable sodium salt of the antisense oligonucleotide splicing regulator of the present invention.

[0362] The present invention provides a pharmaceutically acceptable potassium salt of the antisense oligonucleotide splicing regulator of the present invention.

[0363] Delivery of antisense oligonucleotide splicing modulators

[0364] The present invention provides an antisense oligonucleotide splicing modulator of the present invention, wherein the antisense oligonucleotide splicing modulator is encapsulated in a lipid-based delivery vehicle, covalently linked to or encapsulated in a dendrimer, or conjugated to an aptamer.

[0365] This may be done for the purpose of delivering the antisense oligonucleotide splicing modulators of the invention to target cells and / or improving the pharmacokinetics of the antisense oligonucleotide splicing modulators.

[0366] Examples of lipid-based delivery vehicles include oil-in-water emulsions, micelles, liposomes, and lipid nanoparticles.

[0367] Pharmaceutical composition

[0368] The present invention provides a pharmaceutical composition comprising the antisense oligonucleotide splicing regulator of the present invention and a pharmaceutically acceptable diluent, solvent, carrier, salt and / or adjuvant.

[0369] The present invention provides a pharmaceutical composition comprising the antisense oligonucleotide splicing regulator of the present invention and a pharmaceutically acceptable salt.

[0370] For example, the salt may comprise a metal cation, such as a sodium salt or a potassium salt.

[0371] The present invention provides a pharmaceutical composition of the present invention, wherein the pharmaceutical composition comprises the antisense oligonucleotide splicing regulator of the present invention and an aqueous diluent or solvent.

[0372] The present invention provides a solution, such as a phosphate buffered saline solution of an antisense oligonucleotide splicing modulator of the present invention. In some embodiments, the solution of the present invention, such as a phosphate buffered saline solution is a sterile solution.

[0373] Methods for increasing UNC13A expression

[0374] The present invention provides a method for enhancing, upregulating or restoring the expression of wild-type UNC13A in a cell (such as a cell expressing UNC13A), the method comprising administering an antisense oligonucleotide splicing regulator of the present invention or a pharmaceutical composition of the present invention to the cell in an effective amount.

[0375] In some embodiments, the method is an in vitro method.

[0376] In some embodiments, the method is an in vivo method.

[0377] In some embodiments, the cell is an animal cell, preferably a mammalian cell, such as a mouse cell, a rat cell, a hamster cell, or a monkey cell, or preferably a human cell.

[0378] In some embodiments, the cell is a mammalian cell.

[0379] In some embodiments, the cell is a human cell.

[0380] In some embodiments, the cell is part of, or is derived from, a subject suffering from or susceptible to a disease associated with reduced expression of wild-type UNC13A. Such diseases include, but are not limited to, amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration (FTLD), progressive supranuclear palsy (PSP), primary lateral sclerosis, progressive muscular atrophy, Alzheimer's disease, Parkinson's disease, autism, hippocampal sclerosis dementia, Down syndrome, Huntington's disease, polyglutamine diseases such as spinocerebellar ataxia 3, myopathy, and chronic traumatic encephalopathy.

[0381] treat

[0382] As used herein, the term "treatment" refers to the treatment of an existing disease (eg, a disease or disorder referred to herein) or the prevention (ie, prevention) of a disease. It will therefore be appreciated that in some embodiments, the treatment referred to herein may be prophylactic.

[0383] The present invention provides a method for treating or preventing a disease, which comprises administering a therapeutically or preventively effective amount of the antisense oligonucleotide splicing regulator of the present invention or the pharmaceutical composition of the present invention to a subject suffering from or susceptible to the disease.

[0384] The disease may be associated with reduced expression of wild-type UNC13A.

[0385] In some embodiments, the present invention provides a method for treating or preventing a disease associated with reduced expression of wild-type UNC13A, the method comprising administering a therapeutically or prophylactically effective amount of an antisense oligonucleotide splicing regulator of the present invention or a pharmaceutical composition of the present invention to a subject suffering from or susceptible to a disease associated with reduced expression of wild-type UNC13A.

[0386] In one embodiment, the disease is a nervous system disorder.

[0387] In one embodiment, the disease is selected from the group consisting of amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration (FTLD), progressive supranuclear palsy (PSP), primary lateral sclerosis, progressive muscular atrophy, Alzheimer's disease, Parkinson's disease, autism, hippocampal sclerosis dementia, Down syndrome, Huntington's disease, polyglutamine diseases such as spinocerebellar ataxia 3, myopathy and chronic traumatic encephalopathy.

[0388] In some embodiments, the subject is an animal, preferably a mammal such as a mouse, rat, hamster, or monkey, or a human.

[0389] In some embodiments, the subject is a human.

[0390] The present invention provides the antisense oligonucleotide splicing regulator of the present invention for use as a medicament.

[0391] The present invention provides the antisense oligonucleotide splicing regulator of the present invention, which is used for preparing a drug.

[0392] The present invention provides an antisense oligonucleotide splicing modulator of the invention for use in therapy.

[0393] The present invention provides the pharmaceutical composition of the present invention for use as a medicament.

[0394] The present invention provides the pharmaceutical composition of the present invention, which is used for preparing a medicament.

[0395] The present invention provides a pharmaceutical composition of the present invention for use in therapy.

[0396] The present invention provides the antisense oligonucleotide splicing regulator of the present invention for use as a drug for treating nervous system diseases.

[0397] The present invention provides an antisense oligonucleotide splicing regulator of the present invention for use as a medicament for treating a disease selected from the group consisting of amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration (FTLD), progressive supranuclear palsy (PSP), primary lateral sclerosis, progressive muscular atrophy, Alzheimer's disease, Parkinson's disease, autism, hippocampal sclerosis dementia, Down syndrome, Huntington's disease, polyglutamine diseases such as spinocerebellar ataxia 3, myopathy and chronic traumatic encephalopathy.

[0398] The present invention provides use of the antisense oligonucleotide splicing regulator of the present invention in preparing a drug for treating or preventing nervous system diseases.

[0399] The present invention provides the use of the antisense oligonucleotide splicing regulator of the present invention in the preparation of a medicament for treating or preventing a disease selected from the group consisting of amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration (FTLD), progressive supranuclear palsy (PSP), primary lateral sclerosis, progressive muscular atrophy, Alzheimer's disease, Parkinson's disease, autism, hippocampal sclerosis dementia, Down syndrome, Huntington's disease, polyglutamine diseases such as spinocerebellar ataxia 3, myopathy and chronic traumatic encephalopathy.

[0400] The present invention provides the pharmaceutical composition of the present invention for use as a drug for treating nervous system diseases.

[0401] The present invention provides a pharmaceutical composition of the present invention for use as a medicament for treating a disease selected from the group consisting of amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration (FTLD), progressive supranuclear palsy (PSP), primary lateral sclerosis, progressive muscular atrophy, Alzheimer's disease, Parkinson's disease, autism, hippocampal sclerosis dementia, Down syndrome, Huntington's disease, polyglutamine diseases such as spinocerebellar ataxia 3, myopathy and chronic traumatic encephalopathy.

[0402] The present invention provides use of the pharmaceutical composition of the present invention in preparing a drug for treating or preventing nervous system diseases.

[0403] The present invention provides use of the pharmaceutical composition of the present invention in the preparation of a medicament for treating or preventing a disease selected from the group consisting of amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration (FTLD), progressive supranuclear palsy (PSP), primary lateral sclerosis, progressive muscular atrophy, Alzheimer's disease, Parkinson's disease, autism, hippocampal sclerosis dementia, Down syndrome, Huntington's disease, polyglutamine diseases such as spinocerebellar ataxia 3, myopathy and chronic traumatic encephalopathy.

[0404] Application

[0405] The antisense oligonucleotide splicing regulators of the invention or the pharmaceutical compositions of the invention can be administered topically (such as to the skin, by inhalation, to the eye or to the ear) or enterally (such as orally or through the gastrointestinal tract) or parenterally (such as intravenously, subcutaneously, intramuscularly, intracerebrally, intracerebroventricularly or intrathecally).

[0406] In a preferred embodiment, the antisense oligonucleotide splicing regulator of the invention or the pharmaceutical composition of the invention is administered by a parenteral route, including intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion, intrathecal or intracranial, such as intracerebral or intraventricular administration. In one embodiment, the antisense oligonucleotide splicing regulator of the invention is administered intracerebrally or intraventricularly. In another embodiment, the antisense oligonucleotide splicing regulator of the invention is administered intrathecally.

[0407] The present invention also provides use of the antisense oligonucleotide splicing regulator of the present invention or the pharmaceutical composition of the present invention in the preparation of a medicament, wherein the medicament is in a dosage form for intrathecal administration.

[0408] The present invention also provides use of the antisense oligonucleotide splicing regulator of the present invention or the pharmaceutical composition of the present invention in the preparation of a drug, wherein the drug is in a dosage form for intracerebral or intraventricular administration.

[0409] The present invention also provides use of the antisense oligonucleotide splicing regulator of the present invention or the pharmaceutical composition of the present invention in the preparation of a drug, wherein the drug is in a dosage form for intraventricular administration.

[0410] Combination therapy

[0411] In some embodiments, the antisense oligonucleotide splicing modulators of the invention or the pharmaceutical compositions of the invention are for use in combination therapy with one or more other therapeutic agents.

[0412] Examples

[0413] Example 1: Identification of UNC13A as a novel target for TDP43 mRNA splicing regulation.

[0414] A hallmark feature of ALS disease is the presence of cytoplasmic aggregates of TDP43 protein in a small fraction of the patient's neuronal cells. As a consequence of cytoplasmic aggregates of TDP43, it is depleted in the cell nucleus and thus cannot perform its normal functions in the nucleus.

[0415] TDP43 has been shown to affect mRNA splicing. To identify new genes whose mRNA is regulated by the presence of TDP43, we knocked down TDP43 in a neuronal cell model. The cells were RNA sequenced and de novo transcript analysis was performed to identify affected genes with new splicing patterns.

[0416] Human glutamatergic neurons (Fujifilms) were plated at 60,000 live cells together with 10,000 live astrocytes (Fujifilms) in 96-well plates coated with laminin and poly(ethyleneimine) solution (Sigma Aldrich) in 200 μl of culture medium (day -1).

[0417] To knock down TDP-43, 5 μM of compound A (SEQ ID 553) was added to the culture medium on day 0, and PBS was added to other wells as a control. Half of the cell culture medium was changed 3 times a week throughout the experiment (days 2, 5, 7, 10, 12, 14, and 17). Cells were harvested on day 20 using Magnapure lysis buffer (Roche) and RNA was isolated on the MagNA pure 96 system (Roche) according to the manufacturer's instructions (including the DNase treatment step). KAPA mRNA HyperPrepKit was used. The platform (Roche) prepared NGS libraries from 100ng total RNA. The library was subjected to paired end sequencing with 150-bp read length on the NovaSeq6000 sequencer (Illumina). Data analysis was performed using CLC Genomics Workbench21. The data was first analyzed by running large gap mapping analysis using the hg38 genome assembly, and then transcript discovery was performed. Predicted new splicing events were checked by manual visual inspection to identify true splicing events.

[0418] It was found that upon TDP43 loss, a new exon of 128 (mutant transcript 1) or 178 (mutant transcript 2) base pairs was included in UNC13A. According to the hg38 human gene annotation, the first and last bases in the new exon are; mutant transcript 1: (17,642,541 and 17,642,414), mutant transcript 2 (17,642,591 and 17,642,414), where UNC13A is placed in the negative orientation. This results in the inclusion of a 128 bp or 178 bp exon, both of which result in a frameshift and a premature stop codon that then targets the transcript for nonsense-mediated decay (NMD).

[0419] Example 2: Use of ASO to rescue faulty UNC13A mRNA splicing caused by lack of TDP43.

[0420] Here, we demonstrate the ability of ASOs to induce correct splicing at the TDP43 target UNC13A.

[0421] Human glutamatergic neurons (Fujifilms) were plated with 60,000 live cells and 10,000 live astrocytes (Fujifilms) in 200ul culture medium coated with laminin and poly (ethyleneimine) solution (SigmaAldrich) in each 96-well plate (day -1). In order to knock down TDP-43, 5uM of compound A (SEQ ID553) was added to the culture medium on day 0 (except for four control wells per plate). Half of the cell culture medium was replaced 3 times a week during the entire experiment (days 2, 5, 7, 9, 12, 14, 16, 19). On the 5th day, ASOs targeting recessive UNC13A exons were added to the culture medium at 10uM. A total of 272 different ASOs (SEQ ID 280 to 551) were added. Ten wells per plate received only compound A (SEQ ID 553) as a baseline reference. The experiment was run in duplicate.

[0422] Cells were harvested on day 20 using Magnapure lysis buffer (Roche) and RNA was isolated on a MagNA pure 96 system (Roche) according to the manufacturer's instructions (including a DNase treatment step). Purified RNA was denatured at 90°C for 30 seconds prior to cDNA synthesis. cDNA was generated using the iScript Advanced cDNA Synthesis Kit for RT-qPCR (Biorad) according to the manufacturer's instructions.

[0423] The expression level of the target gene was measured by droplet digital PCR using the QX1 system (Bio-Rad) with QX1 software standard version. The PCR-probe assay for measuring the expression of the normally spliced ​​target mRNA was designed to span two exons, between which a new "mutant" exon would appear.

[0424] The data presented in Table 1 were normalized to the expression of the housekeeping gene HPRT1 and finally to the average expression value of four control wells (PBS) that did not receive any TDP43 knockdown or CA repeat ASO.

[0425] The following PCR probes synthesized at Integrated DNA technologies (IDT) were used:

[0426] TARDBP:

[0427] Primer 1: CAGCTCATCCTCAGTCATGTC,

[0428] Primer 2: GATGGTGTGACTGCAAACTTC,

[0429] Probe: / 5Cy5 / CAGCGCCCCACAAACACTTTTCT / 3IAbRQSp / ,

[0430] UNC13Awt(ex20-ex21):

[0431] Primer 1: GATCAAAGGCGAGGAGAAGG,

[0432] Primer 2: TGGCATCTGGGATCTTCAC,

[0433] Probe: / 56-FAM / ACCTGTCTG / ZEN / CATGAGAACCTGTTCCACTTC / 3IABkFQ /

[0434] The following CY5.5-labeled HPRT1 probe was purchased from BioRad: dHsaCPE13136107.

[0435] Table 1: Production of TDP43 and UNC13A WT after exposure to oligonucleotides. The data presented in Table 1 show the percentiles of gene expression compared to control cells. Data were normalized to the expression of the housekeeping gene HPRT1 and finally to the mean expression value of control wells (PBS) that did not receive any TDP43 knockdown. KD ("knockdown", describes wells that received only treatment with a spacer ASO that degrades TDP43 mRNA)

[0436]

[0437]

[0438]

[0439]

[0440]

[0441]

[0442]

[0443]

[0444]

[0445]

[0446]

[0447]

[0448]

[0449]

[0450]

[0451]

[0452]

[0453]

[0454]

[0455]

[0456]

[0457]

[0458]

[0459]

[0460]

[0461]

[0462]

[0463]

[0464]

[0465]

[0466]

[0467]

[0468]

[0469]

[0470]

[0471]

[0472]

[0473]

[0474]

[0475]

[0476]

[0477]

[0478]

[0479]

[0480]

[0481]

[0482]

[0483]

[0484]

[0485]

[0486]

[0487]

[0488]

[0489]

[0490]

[0491]

[0492]

Claims

1. An antisense oligonucleotide Unc-13 homolog A (UNC13A) splicing regulator, wherein the antisense oligonucleotide splicing regulator is 8 to 40 nucleotides in length and comprises a contiguous nucleotide sequence of at least 8 nucleotides in length that is complementary to UNC13A pre-mRNA. 2 . The antisense oligonucleotide splicing regulator according to claim 1 , wherein the UNC13A pre-mRNA has the sequence of SEQ ID NO:

1. 3 .

3. The antisense oligonucleotide splicing regulator according to claim 1 or claim 2, wherein the antisense oligonucleotide splicing regulator is capable of increasing the expression of Unc-13 homolog A (UNC13A) in TDP-43-depleted cells. 4 . The antisense oligonucleotide splicing regulator according to claim 3 , wherein UNC13A is encoded by the nucleotide sequence of SEQ ID NO: 2 or a fragment or variant thereof. 5 . The antisense oligonucleotide splicing regulator according to claim 3 or claim 4 , wherein the UNC13A protein has the sequence of SEQ ID NO: 3 or a fragment or variant thereof.

6. The antisense oligonucleotide splicing regulator according to any one of claims 1 to 5, wherein the antisense oligonucleotide splicing regulator is capable of reducing the expression of a UNC13A mutant polypeptide in TDP-43-depleted cells. 7 . The antisense oligonucleotide splicing regulator according to claim 6 , wherein the UNC13A mutant polypeptide is a splicing variant of UNC13A.

8. The antisense oligonucleotide splicing regulator of claim 7, wherein the UNC13A mutant polypeptide comprises a polypeptide sequence encoded by an additional exon when compared to the wild-type UNC13A polypeptide sequence.

9. The antisense oligonucleotide splicing regulator of claim 8, wherein the UNC13A mutant polypeptide comprises an insertion when compared to the wild-type UNC13A polypeptide sequence.

10. The antisense oligonucleotide splicing regulator according to any one of claims 6 to 9, wherein the UNC13A mutant polypeptide is encoded by the nucleotide sequence of SEQ ID NO: 4, or a fragment or variant thereof.

11. The antisense oligonucleotide splicing regulator according to any one of claims 6 to 10, wherein the UNC13A mutant polypeptide has the sequence of SEQ ID NO: 5 or a fragment or variant thereof.

12. The antisense oligonucleotide splicing regulator according to any one of claims 6 to 9, wherein the UNC13A mutant polypeptide is encoded by the nucleotide sequence of SEQ ID NO: 6, or a fragment or variant thereof.

13. The antisense oligonucleotide splicing regulator according to any one of claims 6 to 10, wherein the UNC13A mutant polypeptide has the sequence of SEQ ID NO: 7 or a fragment or variant thereof.

14. The antisense oligonucleotide splicing regulator of claim 6, wherein expression of the UNC13A mutant polypeptide is reduced due to nonsense-mediated degradation of mature mRNA.

15. The antisense oligonucleotide splicing regulator according to any one of claims 6 to 14, wherein the contiguous nucleotide sequence is complementary to a splicing enhancer site in the UNC13A pre-mRNA.

16. The antisense oligonucleotide splicing regulator according to any one of claims 1 to 15, wherein the contiguous nucleotide sequence is complementary to SEQ ID NO 554.

17. The antisense oligonucleotide splicing regulator according to any one of claims 1 to 16, wherein the contiguous nucleotide sequence is complementary to SEQ ID NO 555.

18. The antisense oligonucleotide splicing regulator according to any one of claims 1 to 17, wherein the contiguous nucleotide sequence is complementary to SEQ ID NO 556.

19. The antisense oligonucleotide splicing regulator according to any one of claims 1 to 18, wherein the contiguous nucleotide sequence is complementary to SEQ ID NO 557.

20. The antisense oligonucleotide splicing regulator according to any one of claims 1 to 18, wherein the contiguous nucleotide sequence is complementary to SEQ ID NO 558.

21. The antisense oligonucleotide splicing regulator according to one of claims 1 to 20, wherein the contiguous nucleotide sequence is complementary to a sequence selected from SEQ ID NOs 8 to 279.

22. The antisense oligonucleotide splicing regulator of claim 21, wherein the contiguous nucleotide sequence is complementary to a sequence selected from the group consisting of SEQ ID NO: 62; SEQ ID NO: 66, SEQ ID NO: 68, SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 76, SEQ ID NO: 112, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 117, SEQ ID NO: 122, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141 NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 146, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 178, SEQ ID NO: 179, SEQ ID NO: 183, SEQ ID NO: 187, SEQ ID NO: 189, SEQ ID NO: 192, SEQ ID NO: 193, SEQ ID NO: 214, SEQ ID NO: 247, SEQ ID NO: 252, SEQ ID NO: 254, SEQ ID NO: 258, SEQ ID NO: 273, SEQ ID NO: 276, SEQ ID NO:277, SEQ ID NO:278 and SEQ ID NO:

279.

23. The antisense oligonucleotide splicing regulator of claim 22, wherein the contiguous nucleotide sequence is complementary to a sequence selected from the group consisting of SEQ ID NO: 66, SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 76, SEQ ID NO: 122, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 146, SEQ ID NO: 151, SEQ ID NO: 152, NO: 152, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 273, SEQ ID NO: 276, SEQ ID NO: 277 and SEQ ID NO:

279.

24. The antisense oligonucleotide splicing regulator according to any one of claims 1 to 23, wherein the contiguous nucleotide sequence is a sequence selected from SEQ ID NOs 280 to 551, or at least 10 contiguous nucleotides thereof.

25. The antisense oligonucleotide splicing regulator of claim 24, wherein the contiguous nucleotide sequence is a sequence selected from the group consisting of SEQ ID NO: 334; SEQ ID NO: 338; SEQ ID NO: 340; SEQ ID NO: 342; SEQ ID NO: 344; SEQ ID NO: 345; SEQ ID NO: 346; SEQ ID NO: 348; SEQ ID NO: 384; SEQ ID NO: 386; SEQ ID NO: 387; SEQ ID NO: 389; SEQ ID NO: 394; SEQ ID NO: 397; SEQ ID NO: 398; SEQ ID NO: 399; SEQ ID NO: 400; SEQ ID NO: 401; SEQ ID NO: 402; SEQ ID NO: 403; SEQ ID NO: 405; SEQ ID NO: 406; SEQ ID NO: 407; SEQ ID NO: 408; SEQ ID NO: 409; SEQ ID NO: 410; SEQ ID NO: 411; SEQ ID NO: 412; SEQ ID NO: 413; SEQ ID NO: 414; SEQ ID NO: 415; SEQ ID NO: 418; SEQ ID NO: 423; SEQ ID NO: 424; SEQ ID NO: 425; SEQ ID NO: 426, SEQ ID NO: 427, SEQ ID NO: 428, SEQ ID NO: 434, SEQ ID NO: 435, SEQ ID NO: 450, SEQ ID NO: 451, SEQ ID NO: 455, SEQ ID NO: 459, SEQ ID NO: 461, SEQ ID NO: 464, SEQ ID NO: 465, SEQ ID NO: 486, SEQ ID NO: 519, SEQ ID NO: 524, SEQ ID NO: 526, SEQ ID NO: 530, SEQ ID NO: 545, SEQ ID NO:548, SEQ ID NO:549, SEQ ID NO:550 and SEQ ID NO:551, or at least 10 consecutive nucleotides thereof.

26. The antisense oligonucleotide splicing regulator of claim 25, wherein the contiguous nucleotide sequence is a sequence selected from the group consisting of SEQ ID NO: 338, SEQ ID NO: 342, SEQ ID NO: 344, SEQ ID NO: 345, SEQ ID NO: 346, SEQ ID NO: 348, SEQ ID NO: 394, SEQ ID NO: 397, SEQ ID NO: 398, SEQ ID NO: 399, SEQ ID NO: 400, SEQ ID NO: 401, SEQ ID NO: 402, SEQ ID NO: 403, SEQ ID NO: 405, SEQ ID NO: 406, SEQ ID NO: 407, SEQ ID NO: 408, SEQ ID NO: 409, SEQ ID NO: 410, SEQ ID NO: 411, SEQ ID NO: 412, SEQ ID NO: 413, SEQ ID NO: 414, SEQ ID NO: 415, SEQ ID NO: 418, SEQ ID NO: 423, SEQ ID NO: 424, SEQ ID NO: 425 NO:424, SEQ ID NO:426, SEQ ID NO:427, SEQ ID NO:428, SEQ ID NO:434, SEQ ID NO:435, SEQ ID NO:545, SEQ ID NO:548, SEQ ID NO:549 and SEQ ID NO:551, or at least 10 consecutive nucleotides thereof.

27. The antisense oligonucleotide splicing regulator according to any one of claims 1 to 26, wherein the contiguous nucleotide sequence is at least 12 nucleotides in length.

28. The antisense oligonucleotide splicing regulator of any one of claims 1 to 27, wherein the contiguous nucleotide sequence is at least 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 or 32 nucleotides in length.

29. The antisense oligonucleotide splicing regulator according to any one of claims 1 to 28, wherein the length of the contiguous nucleotide sequence is the same as the length of the antisense oligonucleotide splicing regulator.

30. The antisense oligonucleotide splicing modulator of any one of claims 1 to 29, wherein the antisense oligonucleotide splicing modulator is isolated, purified or manufactured.

31. The antisense oligonucleotide splicing regulator of any one of claims 1 to 30, wherein the contiguous nucleotide sequence comprises one or more modified nucleosides.

32. The antisense oligonucleotide splicing regulator according to any one of claims 1 to 31, wherein the antisense oligonucleotide splicing regulator is a morpholino antisense oligonucleotide.

33. An antisense splicing regulator oligonucleotide according to claim 31 or claim 32, wherein the one or more modified nucleosides are 2' sugar modified nucleosides, such as 2' sugar modified nucleosides independently selected from the group consisting of: 2'-O-alkyl-RNA; 2'-O-methyl RNA (2'-OMe); 2'-alkoxy-RNA; 2'-O-methoxyethyl-RNA (2'-MOE); 2'-amino-DNA; 2'-fluoro-RNA; 2'-fluoro-DNA; arabino nucleic acid (ANA); 2'-fluoro-ANA; locked nucleic acid (LNA); or any combination thereof.

34. The antisense oligonucleotide splicing regulator of claim 33, wherein the 2' sugar-modified nucleoside is an affinity-enhanced 2' sugar-modified nucleoside.

35. The antisense oligonucleotide splicing regulator of any one of claims 1 to 34, wherein the contiguous nucleotide sequence of the antisense oligonucleotide splicing regulator comprises 2'-O-methoxyethyl-RNA (2'-MOE) nucleosides.

36. The antisense oligonucleotide splicing modulator of claim 35, wherein all of the nucleosides of the contiguous nucleotide sequence are 2'-O-methoxyethyl-RNA (2'-MOE) nucleosides, optionally linked by phosphorothioate internucleoside bonds.

37. The antisense oligonucleotide splicing regulator according to any one of claims 31 to 36, wherein one or more of the modified nucleosides is a locked nucleic acid nucleoside (LNA), such as an LNA nucleoside selected from the group consisting of constrained ethyl nucleoside (cEt) and β-D-oxy-LNA.

38. The antisense oligonucleotide splicing regulator according to claim 37, wherein the contiguous nucleotide sequence of the antisense oligonucleotide splicing regulator comprises or consists of LNA nucleosides and DNA nucleosides.

39. The antisense oligonucleotide splicing regulator of any one of claims 1 to 38, wherein the contiguous nucleotide sequence is at least 75% complementary to a UNC13A pre-mRNA sequence.

40. The antisense oligonucleotide splicing regulator of claim 39, wherein the contiguous nucleotide sequence is at least 80%, at least 85%, at least 90% or at least 95% complementary to the UNC13A pre-mRNA sequence.

41. The antisense oligonucleotide splicing regulator of any one of claims 1 to 38, wherein the contiguous nucleotide sequence is fully complementary to the UNC13A pre-mRNA.

42. The antisense oligonucleotide splicing regulator of any one of claims 1 to 40, wherein the contiguous nucleotide sequence comprises 1, 2, 3 or more mismatches to the UNC1 3A pre-mRNA sequence.

43. The antisense oligonucleotide splicing modulator according to any one of claims 1 to 42, wherein the antisense oligonucleotide splicing modulator has a Gibbs free energy for a complementary target RNA of less than about -10ΔG, such as less than about -15ΔG, such as less than about -17ΔG.

44. The antisense oligonucleotide splicing regulator according to any one of claims 1 to 43, wherein the antisense oligonucleotide splicing regulator does not comprise a region of more than 3 or more than 4 consecutive DNA nucleosides.

45. The antisense oligonucleotide splicing modulator of any one of claims 1 to 44, wherein the antisense oligonucleotide splicing modulator is not capable of mediating RNase H cleavage.

46. ​​The antisense oligonucleotide splicing regulator according to any one of claims 1 to 45, wherein the antisense oligonucleotide splicing regulator or a contiguous nucleotide sequence thereof is a mixed polymer or a full polymer.

47. The antisense oligonucleotide splicing regulator according to any one of claims 1 to 46, wherein the cytosine bases present in the antisense oligonucleotide splicing regulator or a contiguous nucleotide sequence thereof are independently selected from the group consisting of: cytosine and 5-methylcytosine.

48. The antisense oligonucleotide splicing regulator according to any one of claims 1 to 47, wherein the cytosine base present in the antisense oligonucleotide splicing regulator or a contiguous nucleotide sequence thereof is 5-methylcytosine.

49. The antisense oligonucleotide splicing modulator of any one of claims 1 to 48, wherein one or more of the internucleoside linkages between the nucleosides on the contiguous nucleotide sequence is modified.

50. The antisense oligonucleotide splicing regulator of any one of claims 1 to 49, wherein at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% of the internucleoside linkages between the nucleosides on the contiguous nucleotide sequence are modified.

51. The antisense oligonucleotide splicing modulator of any one of claims 1 to 50, wherein one or more or all of the modified internucleoside linkages comprise phosphorothioate linkages.

52. The antisense oligonucleotide splicing regulator according to any one of claims 1 to 51, wherein all of the internucleoside linkages present in the antisense oligonucleotide splicing regulator are phosphorothioate internucleoside linkages.

53. The antisense oligonucleotide splicing regulator of any one of claims 1 to 52, wherein the antisense oligonucleotide splicing regulator is covalently linked to at least one conjugate moiety.

54. The antisense oligonucleotide splicing modulator according to any one of claims 1 to 53, wherein the antisense oligonucleotide splicing modulator is in the form of a pharmaceutically acceptable salt.

55. The antisense oligonucleotide splicing regulator of claim 54, wherein the pharmaceutically acceptable salt is a sodium salt or a potassium salt.

56. A pharmaceutical composition comprising the antisense oligonucleotide splicing regulator according to any one of claims 1 to 55, and a pharmaceutically acceptable diluent, solvent, carrier, salt and / or adjuvant.

57. A method for increasing UNC13A expression in a cell, such as an in vivo or in vitro method, comprising administering to the cell an effective amount of an antisense oligonucleotide splicing regulator according to any one of claims 1 to 55 or a pharmaceutical composition according to claim 56.

58. The method of claim 57, wherein the cells express abnormal levels of or exhibit depleted levels of TDP-43.

59. A method for treating or preventing a disease in a subject, the method comprising administering to a subject suffering from or susceptible to the disease a therapeutically or prophylactically effective amount of an antisense oligonucleotide splicing regulator according to any one of claims 1 to 55 or a pharmaceutical composition according to claim 56.

60. The antisense oligonucleotide splicing regulator according to any one of claims 1 to 55 or the pharmaceutical composition according to claim 56 for use as a medicament.

61. The antisense oligonucleotide splicing regulator of any one of claims 1 to 55 or the pharmaceutical composition of claim 56 for use in the treatment or prevention of a disease in a subject.

62. The antisense oligonucleotide splicing regulator according to any one of claims 1 to 55 or the pharmaceutical composition according to claim 56, for use in the preparation of a medicament for treating or preventing a disease in a subject.

63. The method of any one of claims 57 to 59 or the antisense oligonucleotide splicing modulator for use according to any one of claims 60 to 62, wherein the disease is a neurological disorder selected from the group consisting of amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration (FTLD), progressive supranuclear palsy (PSP), primary lateral sclerosis, progressive muscular atrophy, Alzheimer's disease, Parkinson's disease, autism, hippocampal sclerosis dementia, Down syndrome, Huntington's disease, polyglutamine diseases such as spinocerebellar ataxia type 3, myopathy and chronic traumatic encephalopathy.

64. The method or antisense oligonucleotide splicing modulator for use according to claim 63, wherein the disease is a neurological disorder selected from the group consisting of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD).

Citation Information

Patent Citations

  • Novel bicyclonucleoside and oligonucleotide analogues

    WO1998039352A1

  • Oligonucleotide analogues

    WO1999014226A2

  • Novel nucleosides and oligonucleotide analogues

    WO2000047599A1

  • L-RIBO-LNA analogues

    WO2000066604A2

  • Human rnase h and oligonucleotide compositions thereof

    WO2001023613A1